Prerpints.org logo
Preprint
Review

Aspartame Safety as a Food Sweetener and Related Health Hazards

Altmetrics

Downloads

255

Views

162

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

05 July 2023

Posted:

07 July 2023

You are already at the latest version

Alerts
Abstract
Aspartame is the methyl-ester of the aspartate-phenylalanine dipeptide. Over time it became a very popular artificial sweetener. However, since its approval by the main food safety agencies, several concerns have been raised related to neuropsychiatric effects and neurotoxicity, due to its ability to activate glutamate receptors, as well as carcinogenic risks by increased production of reactive oxygen species. Within this review we critically evaluated reports concerning the safety of aspartame. Some studies evidenced subtle mood and behavioral changes upon daily high-dose intake below the admitted limit. Epidemiology studies also evidenced associations between daily aspartame intake and higher predisposition for malignant diseases like non-Hodgkin lymphomas and multiple myelomas, particularly in males, but association by chance still could not be excluded. While the debate over the carcinogenic risk of aspartame is ongoing, it is clear that its use may pose some dangers in peculiar cases, such as patients with seizures or other neurological diseases; it should be totally forbidden for patients with phenylketonuria, and reduced doses or complete avoidance are advisable during pregnancy. It would be also highly desirable for every product containing aspartame to clearly indicate on the label the exact amount of the substance and some risk warnings.
Keywords: 
Subject: Medicine and Pharmacology  -   Dietetics and Nutrition

1. Introduction

Due to decreased sugar production throughout the two world wars, artificial sweeteners, also known as non-nutrient sweeteners, gained popularity [1]. Some non-nutritive, low-calorie sweeteners provide a similar taste while bringing 200–300 times less calories than sugar [2]. Saccharin, discovered and used since 1879, was widely regarded at the time as a sugar substitute. James Schlatter, while doing biochemical synthesis experiments with Robert Mazur, accidentally discovered aspartame in 1965, and his employer G.D. Searle immediately started testing of the substance in the hope of producing and commercializing it on a wide scale [3,4] (Figure 1). Aspartame is the methyl ester of the dipeptide formed by L-aspartic acid and L-phenylalanine [5]. It has been found to be 188 times sweeter than sugar while having the same calorie contents per weight unit [6].
In 1973, D. Searle requested from the Food and Drug Administration (FDA) an initial clearance for aspartame. The FDA stated that the maximum daily dosage of aspartame for humans should be 50 mg/kg bodyweight/day in the United States; in Europe a maximal Acceptable Daily Intake (ADI) of 40 mg/kg bodyweight/day was adopted [7]. However, some chronic exposure and carcinogenesis studies [8,9] found even in female rats exposed to relatively low doses of aspartame (4 or 20 mg/kg body weight/day) - exposures that are close to the current ADI in the European Union (40 mg/kg body weight/day) - an increased incidence of malignant tumors.
By 1983, the Equal® brand of aspartame sugar replacement ruled the table-top non-nutritive sweetener industry. Aspartame appealed to diabetics because its dipeptide composition did not require insulin to be metabolized, and it featured a better sweet taste devoid of bitterness and presumably fewer side effects compared to earlier sugar substitutes such as saccharin and cyclamate. Large soft drinks companies such as Coca-Cola® and Royal Crown® declared they will combine two artificial sweeteners, e.g. aspartame and acesulfame K, in their low-calorie diet soda products in order to minimize the side effects of each of them [1,10,11], a guideline followed so far. One year after full approval was obtained, in 1984, NutraSweet® quickly developed into a very lucrative division of G.D. Searle, and the numbers of customers grew less affected by safety concerns [12]. Thus, nowadays aspartame is a common component in over 6000 food products and beverages.
Aspartame is present in soft drinks, dessert mixes, yogurt, chewable multivitamins, and morning cereals. Millions of people throughout the world ingest it because it is also present in 600 different types of medicines [13]. The production of low-calorie beverages, which are widely consumed by youngsters and pregnant people, is a crucial use in the United States [14,15]. Although some early studies estimated that the amount of methanol intake resulting by diet soda drinking in a hot environment can reach 250 mg/day or 32 times the Environmental Protection Agency's daily limit suggestion [16], a more realistic estimate places the methanol intake resulting from daily aspartame consumption in the highest 90% as being 25 times lower than the maximal safe level of methanol intake of 7.1-8.4 mg/kg/day established by FDA, and much lower than the methanol intake resulting from other natural sources such as pectin, fruits, vegetables, alcoholic beverages [17]. A substantial body of literature shows that young animals are more vulnerable than older animals to a variety of chemical and physical carcinogens, particularly during the prenatal period [18]. A reexamination of histopathology data from large groups of animals fed on aspartame-containing diets within studies performed at the Ramazzini Institute in Bologna confirmed that aspartame exposure during pregnancy raises the risk of cancer in rodent offspring [19]. Additional research into associations between aspartame and conditions like brain tumors, brain lesions, and lymphoma has also been advised by several researchers [8,20]. The Food Additives and Nutrient Sources Added to Food Panel evaluated potential risks of aspartame for pregnant women by assessing plasma concentrations of the breakdown product phenylalanine following consumption of aspartame-containing products [7,21].
As consumption is on the rise among the general population, it is essential to create awareness regarding the usage of this artificial sweetener. Therefore, the aim of this review is to summarize the available literature regarding the potential health risks of aspartame (Table A1), including carcinogenesis hazards, with a special emphasis on neurological and psychological effects, integrating evidence gathered in clinical trials, in vivo and in vitro studies and proposing some molecular targets, pathways and mechanisms that may explain these effects (Figure 2).

2. Chemical structure, digestion and metabolism

Aspartame is the methyl ester of a dipeptide composed of a hydrophilic and a hydrophobic amino acid residue, aspartic acid (Asp) and phenylalanine (Phe), respectively, giving it some unique qualities [22,23]. Aspartame in purified solid form is a white crystalline powder that may be stored at temperatures between 30 and 80°C and is extremely stable under dry conditions [24]. At room temperature, its aqueous solution has a half-life of approximately 300 days and reaches the highest stability at a pH of 4.3, which is common for diet sodas. The peptide bonds are hydrolyzed in certain conditions, such as high temperature or basic pH [1].
Aspartame stability in soft drinks has been studied intensively. Thus, it was found that after 50-weeks storage at room temperature of a diet soda, 20% of its aspartame content was de-esterified to α-Asp-Phe, 15% was converted to β-Asp-Phe and β-aspartame, and another 20% was converted into a cyclic dipeptide known as aspartame diketopiperazine (3-carboxyl-methyl-6 benzyl-2.5 diketo-piperazine) [24,25]. Aspartame produces methanol by hydrolysis in highly acidic or alkaline environments. The peptide bonds are also hydrolyzed in more extreme circumstances, releasing the free amino acids. Upon consumption, aspartame is split by several digestive enzymes such as esterases and peptidases into a number of chemical components, including aspartic acid, phenylalanine, and methanol, the latter being further decomposed into formaldehyde and formic acid [26]. Studies with human and pig intestinal microvilli preparations and specific inhibitors showed that aminopeptidases A and W are the most active in decomposing the α-Asp-Phe dipeptide [27]. Another pioneering study proved that Asp-Phe is hydrolyzed by 3 of 4 brush border peptidases and by a cytosolic peptidase different from the seven known isoforms [5]. Similarly, aminoacids and dipeptide intestinal absorption studies [28] showed that although dipeptide absorption mechanisms are present, particularly in the jejunum and ileum [29], α-aspartame is almost entirely decomposed in the intestinal lumen and passes into circulation as Asp (40%), Phe (50%) and methanol (10%) [17,25]. The rates of intestinal absorption of β-Asp-Phe and aspartame diketopiperazine are small [25]. The group of Lewis Stegink was particularly active and performed a number of clinical studies on adults, children and infants involving acute (single-dose or repeated doses over less than 1 day) or prolonged (e.g. daily for 13 consecutive weeks) intake of aspartame doses sometimes higher than the ADI (up to 200 mg/kg body weight) (Table A1) to assess the pharmacokinetics and demonstrate lack of toxicity of aspartame decomposition products [30,31,32,33,34,35,36,37,38], except for subjects with genetic traits resulting in low plasma α-Asp-Phe hydrolase activity [39]. However, other clinical studies reached different conclusions, showing adverse effects of aspartame, particularly in subjects with neurological or psychiatric conditions, such as migraine [40,41], other headaches [42,43], or unipolar depression [44]. Part of these differences may result from the fact that aspartame was administered in some studies, e.g. [44], as powder included in enteric-soluble capsules, which can release very high concentrations of aspartame over limited areas of intestinal mucosa, in contrast to administration in pre-dissolved form in water or beverages.
While phenylalanine is turned into tyrosine and phenylethylamine, and methanol is converted into formaldehyde, which then undergoes an oxidation reaction to formic acid, aspartic acid is converted to alanine and oxaloacetate [45]. Each of these compounds is metabolized according to a natural metabolic route in the same manner as those originating from foods and other dietary sources. As demonstrated in animals, methanol from aspartame enters the portal circulation and is promptly converted by alcohol dehydrogenase to formaldehyde, which is further transformed into formate by aldehyde dehydrogenase [13]. Early pharmacokinetics and metabolism studies in humans have shown that upon acute ingestion of 50 mg/kg aspartame blood methanol levels increased to 0.34±0.12 mg/dl (mean ± SEM, n=6) in adults 30 to 90 min after intake, and to 0.30±0.10 mg/dl in infants; higher aspartame doses produced proportionally higher peak blood methanol levels [31,32]. However, several researchers have pointed out that methanol levels resulting from aspartame intake are several times smaller than those produced by consumption of other common foods and drinks, like fruits or vegetables juices and fermented distilled beverages, due to enzyme-driven breakdown of methoxyl groups of polysaccharides such as pectin [17,31]. Therefore, aspartame side-effects are more likely due to the two aminoacids released by its decomposition, phenylalanine and aspartate. Thus, a clinical study on children fed with aspartame 34 mg/kg/day for two weeks proved increased phenyalanine and tyrosine plasma levels compared to a placebo group [46].
Increased phenylalanine concentrations are linked to lower levels of catecholamines, serotonin, and dopamine [47]. Phenylalanine is a large neutral amino acid that competes with other amino acids for binding on the large neutral amino acid transporter [48]. Phenylalanine released from aspartame may theoretically mediate neurologic effects since it has neurotoxic potential and influences the production of monoamine neurotransmitters. When pentylenetetrazole, an epileptogenic drug, is administered to mice after aspartame administration, the frequency of seizures that follow is increased [49]. This is because aspartame causes plasma phenylalanine levels to rise more than those of tyrosine (which likely happens after any aspartame dose in humans). Phenylalanine prevents dopamine release in the striatum, whereas valine, which competes with phenylalanine for passage across the blood-brain barrier, can alleviate its proepileptogenic effect [50]. Reduced levels of dopamine and serotonin are a result of the excess phenylalanine blocking the transport of crucial amino acids to the brain. In addition to being employed in protein synthesis, phenylalanine can also be converted into the highly concentrated phenylpyruvic acid in phenylketonuria patients [51,52]. By competing for neutral aminoacids transporters, phenylalanine can directly affect the entry of other critical amino acids into the CNS. As a result, it indirectly influences neurotransmitter deficiencies that result in functional problems [53].
On the other hand aspartate, the carboxylate anion of aspartic acid, undergoes transamination in enterocytes to become oxaloacetate before reaching the portal circulation [17]. The urea cycle and gluconeogenesis can be affected by the body's conversion of oxaloacetate and aspartate [2]. Aspartate and other related amino acids, such as asparagine, glutamate, and glutamine, did not significantly change their plasma levels in healthy people after taking aspartame doses of 34 and 50 mg/kg [36]. Aspartic acid residues are frequently found in proteins. The body may convert aspartic acid into the neurotransmitter glutamate, which at very high levels can have harmful effects on the nervous system. In addition, high doses of aspartate can directly activate N-methyl-D-aspartate (NMDA) receptors, exerting excitotoxicity and other central nervous system adverse effects. However, European Food Safety Association’s experts did not see any evidence of neurotoxicity associated with aspartame and therefore concluded that aspartic acid derived from aspartame does not raise any safety concerns for consumers [7].

3. Mechanisms of toxicity of aspartame metabolism products

The fundamental tenet of toxicology is that all substances are harmful at some concentration. As a result, it is not surprising that aspartame or its components have negative effects on sensitive animal species when consumed at very high doses. Upon testing the effects of various aspartame doses on blood levels of aspartate, phenylalanine, and methanol, several studies proved that these levels were well below those associated with adverse effects in animal species, raising the important question of whether aspartame ingestion is potentially harmful to humans during normal use or abuse, in spite of the fact that the dietary exposure of consumers to these compounds is higher than that resulting from aspartame intake [34]. Although FDA and other regulatory agencies have established permissible daily intake guidelines for aspartame ingestion, there are many questions about its safety today.
Frequent high-dose aspartame intake may have nephrotoxic effects. Thus, according to experimental data from different animal species, long-term consumption of aspartame caused a dose-dependent increased production of free radicals in renal tissues as well as kidney injury, as proved by a search of several literature databases for publications on adverse effects of aspartame on the kidney function from 1980 to 2016 [54]. Additionally, recent cohort studies showed a link between excessive aspartame use and an elevated risk for cardiovascular disorders [55]. The administration of aspartame caused oxidative stress and markedly reduced the activity of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase in both rat liver and renal tissues [56]. Increased pro-oxidant levels, such as reactive oxygen and nitrogen species (ROS/RNS), or decreased antioxidant levels, which could cause cell malfunction and disintegration, are indicators of oxidative stress [57].
Several in vivo and in vitro studies revealed altered scavenging mechanisms, increased lipid peroxydation, and enhanced generation ROS/RNS in the erythrocytes or serum of aspartame-treated animals [58,59,60] or in human neuroblastoma cells [61]. The imbalance in ROS/RNS neutralization induced by aspartame can affect neutrophil adhesion, the phagocytic index as well as antibody titers and soluble immune complexes in phagocytic and immune system cells including neutrophils and lymphocytes [59]. A cohort study proved that high aspartame intake during pregnancy increased the risk of developing asthma and allergic rhinitis in offspring [62].
Other studies have shown that aspartame use may increase the chance of developing cancer. Thus, multiple epidemiology follow-up studies on large cohorts have revealed higher incidences of different cancers among high-dose chronic aspartame users [63,64,65]. High doses of aspartame (15 and 30 mM) were found to be cytotoxic in vitro on a human colorectal carcinoma cell line, also promoting chorioallantoic membrane angiogenesis in ovo and having a mild irritating potential at vascular level [66]. In both in vitro and in vivo settings, aspartame had a stimulatory effect on angiogenesis [67,68,69]. Low levels of aspartame administration (less than 40 mg/kg/day) were linked to an increase in oxidative stress in the spinal cord [70]. Similar effects of oxidative stress may occur in immune system cells such as different lymphocyte subsets, altering innate and adaptive immunity, and increased cortisol levels may result in supplementary immunosuppression favoring proliferation of malignant cells [59,71]. These findings shed new light on aspartame’s involvement in the development of cancer, but further research is required to fully understand this phenomenon. Although a systematic meta-analysis of the literature did not retrieve on the average a positive association between aspartame consumption and occurrence of cancer, this analysis was limited to clinical data, excluding a large number of animal studies [72]; other epidemiology studies on large cohorts found increased odds ratios for association of aspartame consumption with non-hodgkin lymphomas and multiple myelomas in male subjects [65]. In a more recent study, Guercio et al. found that patients with stage III colon cancer who consumed more artificially sweetened beverages had significantly lower rates of cancer recurrence and mortality [73].
Aspartame at low doses (up to 170 µM) significantly altered the mRNA expression of apoptotic genes in HeLa cells, up-regulating the expression of the antiapoptotic gene Bcl-2 while down-regulating the expression of the tumor suppressor gene p53 and the apoptotic gene Bax [74]. A recent study on human umbilical vein endothelial cells challenged with doses between 0.01 and 1 mM for 1-4 days likewise showed that aspartame at low concentrations exerted no cytotoxic effects [75]. However, higher doses of aspartame (1-20 mM) significantly inhibited cell growth and induced apoptosis of HeLa cells upon incubation for 24-48 h [76]. Another in vitro experiment conducted on endothelial cells and fibroblasts revealed that aspartame (up to 100 µM) increased the production of ROS linked to the cytotoxic effect, raised the level of the inflammatory mediator IL-6, and had a pro-angiogenic effect by inducing the production of regenerative cytokines and activating the mitogen-activated protein kinase (MAPK) pathway [67]. Animal studies of aspartame administration during pregnancy evidenced reduced placental, maternal and fetal weight and umbilical cord length [77], as well as rupture of interhemal membranes of the placenta, lysis of trophoblast cells and increased vascular endothelial growth factor (VEGF) staining [78].

4. Neurological and cytotoxic effects by activation of NMDA and other glutamate receptors by aspartame or its metabolites

Glutamate represents the main excitatory neurotransmitter in the central nervous system. Glutamate receptors are divided into two groups: metabotropic glutamate receptors (mGluRs), with seven transmembrane α-helical segments accomodating the ligand molecule at the center, similar to rhodopsin, and ionotropic glutamate receptors (iGluRs), tetrameric ligand-gated ion channels with large extracellular domains featuring multiple ligand-binding sites and four transmembrane α-helical segments per subunit. The three types of ionotropic glutamate receptors - NMDA, AMPA, and kainate receptors - are distinguished by varying ion selectivity, activating agents and pharmacological agonists and inhibitors [79]. The N-methyl-D-aspartate receptors (NMDAR) are crucial molecular components of learning and memory via the complex phenomenon of long-term potentiation (LTP), which involves receptor phosphorylation triggered by calcium influx upon repeated stimulation [80]. However, several pathological conditions such as ischemic stroke or neurodegenerative diseases may lead to excitotoxicity, consisting in excessive synaptic glutamate release, NMDAR overactivation with massive Ca2+ inflow resulting in neuronal cell death [81]. The same author pointed out that the developing human brain is exposed to excitotoxic compounds such as those present in foods to a much larger extent compared to the adult brain due to an immature blood-brain barrier [82]. Therefore it seemed logical to express similar concerns over the use of aspartame, since the compound itself and its decomposition product aspartate may effectively activate NMDARs [83], in addition to neurotransmitter imbalances caused by aspartate and phenylalanine [47,50].
Early in vitro assays revealed that aspartame, as well as L-aspartate, may directly act on the NMDA glutamate recognition sites in brain synaptic membranes because it significantly changed the affinities of l-[3H]-glutamate binding without changing the Vmax of binding [84]. Further, Ca2+ inflow via activated NMDARs can trigger calmodulin-dependent activation of different tyrosine kinases and neuronal nitric oxide synthase (nNOS), and the increased NO production would result in higher levels of reactive oxygen and nitrogen species. Indeed, numerous in vivo studies evidenced markers of oxidative stress in animals on aspartame diet compared to control groups in the brain and other tissues such as liver, kidney, blood cells including erythrocytes, neutrophils and lymphocytes (Table A1). These markers are represented by increased levels of superoxide, peroxide and lipid peroxidation, decreased levels of reduced glutathione, glutathione reductase and nitrite, increased activity of free radicals scavenging enzymes like superoxide dismutase and catalase [60,70,85,86,87,88,89,90]. Free radicals produced in large amounts can damage membranes by peroxidation of unsaturated fatty acids in the phospholipids that make up the bilayer [57].
Some experimental studies found increased Na+/K+ ATPase activity in membrane fractions from the midbrain of aspartame-fed rats [91], while other studies found decreased activity in folate-deficient rats on aspartame diet [51,70] or in rat hippocampus homogenates or pure Na+/K+ ATPase incubated with aspartame metabolites [92]. Furthermore, aspartame-fed folate-deficient rats showed in different brain regions reduced levels of phosphorylated NMDAR1 subunits, increased iNOS and nNOS expression and NO production [51]. The central nervous system can express all three isoforms of nitric oxide synthase (Ca2+-sensitive nNOS and eNOS, and Ca2+-independent iNOS), which produce nitric oxide (NO), further converted into the powerful free radical peroxynitrite [93]. When the body's capacity to neutralize and eliminate ROS is surpassed, increasing oxidative stress is a potential threat [94]. This mechanism possibly underlies neuronal damage in multiple brain regions evidenced by several animal studies upon intake of aspartame [51,89,95,96] or L-aspartate [97]. In aspartame-exposed rats with early-life exposure to NMDAR antagonists, significant drug/diet interactions were reflected in glucocentric and behavioral measures. This suggests a potential role for early NMDAR interactions in aspartame-induced behavioral impairments and altered glucose homeostasis [10]. Nitric oxide/cGMP/glutamate release could be modulated by aspartame or aspartate stimulation of NMDA receptors along the sensory pathways, affecting reactivity to pain. This hypothesis is in agreement with the presence of functional NMDARs in approximately 32% of trigeminal primary sensory neurons in rat [98,99]. Aspartame would be an effective analgesic if combined with a calcium channel blocker or NOS inhibitor [100].
These multiple biochemical effects of aspartame and its metabolites on the nervous system may explain the changes in behavioral tests recorded in different in vivo studies for aspartame-fed animals relative to control groups. One common finding was the alteration of spatial orientation resulting in longer escape latenices in maze tests such as the Morris water maze or Y-maze upon intake of aspartame [10,51,101] or impaired flexibility of spatial memory for aspartate [102]. Another important effect is increased anxiety, explaining immobility, diminished ambulation and grooming [95], poorer performance in open field tests [10] and elevated maze-plus tests [103], reduced aggression, lengthened intervals between attacks, reduced number of bites per session [104], increased latency to reward [91], and decreased latency in passive avoidance tests for aspartate-fed mice [97]. Similar phenomena consisting in signs of depression and poor spatial orientation, without effects on working memory, were evidenced in an outstanding clinical trial on healthy young student volunteers fed for 8 days on a high-aspartame diet containing 25 mg/kg/day [105]. Other behavioral changes found in clinical trials were difficulty sitting still and paying attention for a preschool child with low plasma α-Asp-Phe hydrolase activity on aspartame diet [39], depression, insomnia, trouble remembering and irritability for patients with unipolar depression given aspartame 30 mg/kg/day [44], as well as migraine and other types of headache, a common occurrence [40,41,42,43]. Several comprehensive reviews on neuropsychiatric effects related to aspartame consumption are available [17,21,47,48,50,53,71,83,106,107,108].

5. Conclusions

Aspartame is an additive used to sweeten a variety of beverages and foods such as desserts, cakes, chewing gum, yogurt, low calorie and weight control products, and even drugs for oral administration. Its presence in foods can be indicated either by name or by its code E951. Following ingestion, aspartame breaks down in the gut into three constituents: aspartic acid, phenylalanine and methanol. These components are also naturally present in other foods including fruits and vegetables and, for foods containing aspartame, they are processed by the body in the same way as those derived from other dietary sources. Following a detailed and methodical analysis, European Food Safety Association [7] experts concluded that aspartame and its breakdown products are safe for human consumption at current levels of exposure. The current ADI is considered to be safe for the general population, although some clinical [105] or in vivo animal studies [95] suggested neurobehavioral effects upon daily aspartame intake below or at ADI.
Questions have primarily been raised about the early experimental animal studies used to evaluate the safety of aspartame. Some subsequent studies concluded that there is sufficient scientific evidence to confirm that aspartame is generally safe for human consumption up to the maximally recommended daily intake doses. However, its use may pose health risks for certain individuals like patients with seizures or other neurological conditions, it is strictly forbidden for patients with phenylketonuria, and should be restricted if not completely eliminated during pregnancy. It is also highly advisable that each aspartame-containing product lists explicitly the exact amount of aspartame on its label. The association of high-dose aspartame usage and increased risk of developing cancers such as brain tumors or non-Hodgkin lymphomas is still highly controversial and under investigation, and seems to be confirmed by some recent cohort studies.

Funding

This research received no external funding.

Data Availability Statement

We encourage all authors of articles published in MDPI journals to share their research data. In this section, please provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study. Where no new data were created, or where data is unavailable due to privacy or ethical restrictions, a statement is still required. Suggested Data Availability Statements are available in section “MDPI Research Data Policies” at https://www.mdpi.com/ethics.

Acknowledgments

The authors gratefully acknowledge support from colleagues at Faculty of Biology, University of Bucharest and Babylon Technical Institute, Al-Furat Al-Awsat Technical University.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Table A1. Synopsis of epidemiology, clinical, in vivo and in vitro studies exploring different effects and health hazards of aspartame.
Table A1. Synopsis of epidemiology, clinical, in vivo and in vitro studies exploring different effects and health hazards of aspartame.
Study Method Experimental groups Main results
Epidemiology studies
Lim et al. 2006 [109] Clinical cohort prospective study to assess the risk of hematopoietic cancers or malignant gliomas associated with aspartame consumption 285,079 men and 188,905 women aged 50 to 71 years with aspartame consumption assessed via a self-administered food frequency questionnaire, followed up for 5 years (1995–2000). 1,888 hematological malignancies and 315 malignant gliomas were identified over the 5-year period; higher aspartame intake was not linked to an increased risk of hematological cancer (RR 0.98) or glioma (RR 0.73) in either men or women.
Schernhammer et al. 2012 [65] Longitudinal prospective cohort study 1324 non-Hodgkin lymphomas (NHL), 285 multiple myelomas (MM), and 339 leukemias were isolated from two large patient cohorts that were studied for more than 20 years; participants were divided into habitual diet soda drinkers (1 daily serving) and non-consumers. In males but not in women, diet soda consumption was linked to an elevated risk of NHL (RR 1.31), and MM (RR 2.02). Men who drank more soda had a higher risk of developing NHL (RR 1.66). A coincidental association cannot be ruled out.
Maslova et al. 2013 [62] Prospective longitudinal cohort study 60,466 women enrolled during pregnancy in the prospective longitudinal Danish National Birth Cohort between 1996 and 2003; validated food frequency questionnaire adminstered at gestation week 25; child asthma evaluated at 18 months. Childern of artificially-sweetened carbonated drinks consumers were more likely to have asthma (OR 1.30, 95%CI: 1.01-1.66) and take specific medication (OR 1.13, 95%CI: 0.98-1.29), as well as self-reported allergic rhinitis (OR 1.31, 95%CI: 0.98-1.74) during the first 7 years of follow-up.
Bassett et al. 2020 [63] Prospective cohort study 41,513 subjects aged 27 to 76 years at recruitment, of which 6,404 were excluded due to preexisting cancer, angina/heart attack, diabetes, placement in top/bottom 1% of energy consumption or missing data. Over 19 years of follow-up, 4789 of the 35,109 selected participants developed cancers not related to obesity; subjects with high intake of artificially sweetened drinks had a significant hazard ratio of cancer development compared to control (HR 1.23; 95%CI: 1.02-1.48; p-trend 0.006).
Debras et al. 2022a
[64]		 Longitudinal follow-up cohort study NutriNet-Santé web-based cohort included 128,343 volunteers aged >18, of which 102,865 participants were selected and monitored over a median follow-up time of 7.8 years via daily 24h dietary records High consumers of total artificial sweeteners had higher overall risk of cancers (HR 1.13, p-trend 0.002); for high-dose aspartame consumers HR 1.15, p =0.002; higher risks were detected for breast (HR 1.22, p=0.036) and obesity-related cancers (HR 1.15, p=0.026).
Debras et al. 2022b
[55]		 Longitudinal follow-up cohort study NutriNet-Santé web-based cohort included 103,388 selected participants, classified at baseline for diet, health, height and weight, lifestyle and socio-demographic data, physical activity, were monitored for dietary records and with biannual health questionnaires over the period 2009-2021 Total artificial sweeteners (HR 1.09, p=0.03) and aspartame (HR 1.03, p=0.49) were associated with cardiovascular dieseases, coronary heart diseases and cerebrovascular diseases; aspartame intake was associated with cerebrovascular events (HR 1.17, p=0.02).
Clinical studies
Stegink et al. 1979 [36] Randomized cross-over design An overdose of aspartame (100 mg/kg body weight) was delivered to 6 fasting adult volunteers (3 men and 3 women) in both solution and slurry form. Plasma aspartate increased from 0.16±0.05 (mean±SD) to 0.43±0.23 µM (solution) or 5.8 µM (slurry form), phenylalanine from 5 to 20.3±2.05 or 26.0±18.9 µM, methanol increased to 1.16±0.47 or 1.27±0.48 mg/dl at 60-90 min after loading, far below toxic levels.
Stegink et al. 1981 [32] Randomized cross-over design 30 healthy normal adult participants (15 men and 15 women) received different doses of aspartame p.o.: 12 subjects (6 male, 6 female) 34 mg/kg, and 6 subjects in each group were given 100, 150, and 200 mg/kg. No differences on ophthalmologic examinations performed before and after aspartame loading, and no alterations in blood chemistry profile 24 hours after aspartame ingestion.
Stegink et al. 1983 [31] Clinical study of blood methanol levels in one-year-old infants administered graded doses of aspartame 24 infants aged between 8 and 14 months were tested in 3 stages: 10 subjects received aspartame 34 mg/kg, subsequently 6 subjects received 50 mg/kg, and 8 subjects 100 mg/kg body weight. At 34 mg/kg blood methanol levels were below limit of detection (0.35mg/dl), at 50 mg/kg 0.30±0.10 mg/dl, at 100 mg/kg 1.02±0.28 mg/kg, non-toxic and similar to those observed in normal adults.
Stegink et al. 1987 [34] Balanced Latin square design to test effects of co-ingestion of monosodium L-glutamate with aspartame 12 healthy normal adult participants (6 males, 6 females) were adminsitered three distinct soup/beverage meals: meal A with no aspartame (APM) or monosodium L-glutamate (MSG); meal B with 50 mg MSG per kg body weight; meal C with 50 mg MSG and 34 mg APM/kg body weight. Plasma glutamate levels increased significantly after meals B and C, and aspartate levels after meal C; plasma Glu+Asp mean levels increased from baseline (5.64±2.62 µM) to 23.1±7.29 µM (meal B) or 26.8±9.74 µM (meal C).
Koehler and Glaros 1988 [40] Controlled double-blind randomized cross-over study on the frequency and intensity of migraine 11 subjects with migraine history were exposed for 13 weeks to either 1200 mg aspartame/day or placebo and then switched regime after a wash-out period. Aspartame ingestion by migraineurs caused a significant increase in headache frequency (p=0.0144).
Schiffman et al. 1987 [42] Double-blind cross-over clinical trial 40 subjects with history of headache/related neurological symptoms within 24h after aspartame intake were challenged with 30 mg/kg aspartame or placebo The incidence of headache after aspartame ingestion (35%) or placebo (40%) were not different (p=0.5); the subjects with headache had lower plasma concentrations of epinephrine (p<0.0002) and norepinephrine (p<0.02).
Stegink et al. 1988 [35] Two-stage clinical trial in a standard cross-over design 8 healthy normal adult subjects (4 males, 4 females), were given in stage 1 3 servings of unsweetened beverage, and in stage 2 3 servings of beverage providing aspartame 10 mg/kg body weight each. Addition of aspartame had no effect on plasma aspartate levels, and increased phenylalanine levels by 1.64-2.05 µM above baseline (5.09 ±0.82 µM), not exceeding normal postprandial values.
Stegink et al. 1989 [38] Balanced cross-over design 6 normal healthy adult subjects (3 male, 3 female) were given 8 beverage servings at 1h intervals, unsweetened or providing 600 mg aspartame per serving. Plasma phenylalanine levels increased by 1.41-2.35 µM above baseline 30 min after ingestion of aspartame-containing drinks and reached steady-state after 4-5 servings.
Walton et al. 1993 [44] Cross-over design Initally designed to test 40 patients with unipolar depression and a similar control group; final groups were of 8 depression patients and 5 control subjects, given aspartame 30 mg/kg/day or placebo for 7 days. Patiens with depression given aspartame experienced more frequenty symptoms like nausea, depression, insomnia, temper, nervousness, dizziness, trouble remembering, fatigue, malaise, irritability.
Van den Eeden et al. 1994 [43] Double-blind cross-over study on volunteers with self-identified headaches 18 subjects with headaches were randomly administered aspartame 30 mg/kg/day and placebo for 7 days in a 2-phase trial. Headache incidence was 33% on aspartame regime vs. 24% on placebo (p=0.04), with no signifcant difference in length of headache or occurrence of associated side effects.
Shaywitz et al. 1994 [46] Randomized double-blind placebo-controlled crossover study Unmedicated children with attention deficit disorders (DSM3 criteria) given aspartame 34 mg/kg/day single morning dose or placebo for 2 weeks were tested by parents at home and teacher (at school); during a 2-day admission to a study center cognitive tests and blood sampling were performed. No changes in cognitive and behavioral tests (matching familiar figures, children’s checking task, airplane, Wisconsin card sorting, subjects treatment emergent symptom scale, multgrade inventory for teachers, Conners behavior rating scale) and biochemical values, except for plasma Phe and Tyr
Stegink et al. 1995 [39] Clinical trial including biochemistry and behavioral data on children described by their parents as sensitive to sugar vs. normal children 25 normal preschool children (aged 3-5) and 23 school-aged sugar-sensitive children (aged 6–10) were fed diets with high sucrose, aspartame, or saccharin for 3 weeks each, with blood samples at baseline (while fasting) and within the last 3 days of each dietary session. No biochemical or behavioral abnormalities, except for a subject with low plasma a-Asp-Phe hydrolase activity (> 2 SD below the mean) who experienced difficulty sitting still and paying attention towards the end of an aspartame diet session.
Spiers et al. 1998 [110] Randomized double-blind placebo-controlled cross-over study 48 healthy volunteers kept in control conditions for 1 month, then fed with high (45 mg/kg/day), low (15 mg/kg/day) or no aspartame (placebo or sucrose) for 20 days; neuropshychology and laboratory testing was performed at 10 and 20 days under each regime. Plasma phenylalanine concentrations increased significantly during aspartame diet. By sex and by therapy, amino acid, insulin, and glucose readings, EEG, unfavorable experiences, and neuropsychological tests results were compared: there were no significant changes.
Newman and Lipton 2001 [41] Clinical case reports Two recurrent migraine cases:
1. a 14-year-old male with a 2-year migraine history
2. a 36-year-old woman with migraines without an aura for 30 years. 		After receiving treatment with a rizatriptan formulation that contains aspartame (Maxalt-MLT), both patients experienced headache aggravation.
Lindseth et al. 2014 [105] Double-blinded repeated-measures within-subjects neurobehavioral study
to determine differences in cognition, mood, depression, headaches following consumption of high vs. low amounts of aspartame 		28 healthy young adults (students) followed a study-prepared high-aspartame diet (25 mg/kg body weight/day) for 8 days and a low-aspartame diet (10 mg/kg body weight/day) for 8 days, with a 2-week washout period in between the diets. Participants on high aspartame diets were more agitated (p=0.002, paired t test), showed greater signs of depression (p=0.001), and struggled on spatial orientation tests (p=0.03), but with no effect on working memory.
Solomi et al. 2019 [111] Cross-over design to test the acute glycaemic effects of non-nutritive sweeteners aspartame and acesulfame-K 10 healthy volunteers (4 males, 6 females), with a mean age and BMI of 27.2±6.9 years and 23.9±2.4 kg/m2) were tested for glycemia while fasting and at 15-min intervals for 2h after ingesting 236 mL of sucrose-sweetened cola with 125 mL of water, 25 g of glucose in 125 mL of water, and 25 g of glucose in 125 mL of water with 236 mL of diet cola. None of the test beverages had significantly different glycaemic responses; co-consuming artificially sweetened diet cola with a drink containing glucose had no discernible impact on postprandial glycaemia.
In vivo studies
Neurological effects
Torii et al. 1986 [112] Biochemistry and behavioral study in rats Male Sprague-Dawley rats were fed with different combinations of casein, sucrose, corn starch, aspartame (5% of diet weight) for 2h (acute exposure) or for 3 weeks (chronic exposure). Acute aspartame ingestion increased plasma and brain Phe and Tyr levels, but not Trp levels. Brain norepinephrine and dopamine levels were unaltered, serotonin levels were slightly increased on a protein-free diet. Chronic ingestion produced no signifcant chemical changes in brain.
Sharma and Coulombe 1987 [113] Neurochemistry study in mice Male CD-1 mice were given daily aspartame oral doses of 0, 13, 133, 650 mg/kg for 30 days. Increases in adrenergic chemicals noticed after a single dose were not present upon chronic exposure. Serotonin was decreased in several brain regions, possibly due to the fact that increased Phe uptake decreased Trp uptake by brain tissue.
Goerss et al. 2000 [104] Behavioral and neurochemistry study in rats Aspartame (200-800 mg/kg i.p.) or a vehicle was given to adult male Long-Evans rats: 71 rats were used for behavioral testing, while 24 rats were used for a neurochemistry investigation. High-dose aspartame dramatically reduced aggression, lengthened the intervals between attacks, reduced the number of bites per session, and markedly raised serotonin levels in the striatum.
Christian et al. 2004 [91] Behavioral and neurochemistry study of chronic aspartame consumption in rats Male Sprague-Dawley rats (225 g) that received aspartame (250 mg/kg/day) in water for three to four months vs. control rats. The animals were tested for latency to reward retrieval in a T-maze; after brain removal, membrane preparations from specific areas or whole brain were assessed for binding of [3H]quinuclidinyl benzilate and Na/K ATPase activity. In aspartame-treated animals the number of muscarinic chlolinergic receptors increased by 31%; the frontal cortex, midcortex, posterior cortex, hippocampus, hypothalamus, and cerebellum all revealed substantial increases in muscarinic receptor densities, as well as significant increases in Na/K ATPase activity only in the midbrain. Latency to reward increased significantly in aspartame group after 3 and 4 months.
Collison et al. 2012 [101] Behavioral and biochemistry study on spatial cognition, learning, memory, and insulin sensitivity in mice exposed to aspartame C57Bl/6J mice of both sexes were exposed to aspartame or control diet since in utero until 17 weeks of age. Male aspartame-fed mice gained weight, had higher fasting blood sugar levels (noticed also in females) and lower insulin sensitivity at 17 weeks compared to controls (p<0.05). Male aspartame-fed mice had longer escape latencies during spatial learning trials in the Morris water maze test.
Iyashwami et al. 2015 [95] Neurobehavioral and biochemistry study in rats Wistar male albino rats (200-220g, control or kept on folate-deficient diet 45 days and methotrexate-treated for 1 week) were given aspartame 40 mg/kg/day or saline p.o. for 90 days. Anxiety was assessed by open field and elevated maze plus tests. Subsequently animals were sacrificed, blood (for formate levels) and brain samples (for hydrogen peroxide, immunohistochemistry, Western blot immunoassay and RT-PCR for TNF-a, JNK3, Fas, Caspase 8 and 9 vs. b-actin) were collected. Aspartame and methotrexate-treated rats showed immobility, fecal bolus and a clearly diminished level of ambulation, rearing, and grooming, increased anxiety, increased plasma formate, increased hydrogen peroxide generation in different brain areas, increased expression and neuronal staining with apoptosis markers.
Iyashwami et al. 2018 [51]
 Behavioral and neurobiochemistry study in rats Three groups of male Wistar albino rats were selected randomly: saline control, folate-deficient (MTX-treated) control, folate-deficient (MTX-treated) group fed with aspartame 40 mg/kg for 3 months. Aspartame-treated rats showed decline in memory tests (Morris water maze, Y maze), reduced body weight, increased plasma corticosterone levels, nitric oxide production, ACh-esterase activity, c-Fos, hsp70, iNOS and nNOS expression, microglia and astrocyte activation, as well as reduced Na/K ATPase activity and expression of NMDAR1, PSD95, synaptophysin, ERK, CaMKII, CREB in different brain regions.
Magalhães et al. 2019 [103]
 Behavioral and electrophysiology study in rats
 80 newborn Wistar rats were placed into 4 groups, each receiving aspartame 75 mg/kg/day or 125 mg/kg/day (groups ASP75 and ASP125), water (vehicle group), or no treatment (naïve group). Early aspartame ingestion resulted in weight loss, anxiety (shorter times in open arms in elevated maze-plus test), and decreased cortical spreading depression (CSD) velocity via in vivo electrical brain recordings.
Neurological effects of aspartate
Park et al. 2000 [97] Behavioral and histopathology study in mice Male ICR mice (6-7 weeks, 25-30g) were administered a unique dose of 4.0 mg/g monosodium glutamate (MSG) or 0.5 mg/g aspartate (Asp) i.p., or the same amount of saline solution in the control groups. MSG or Asp significantly damaged neurons in the arcuate nucleus of the hypothalamus, with no alterations in the cerebral cortex or hippocampus, or in any other brain regions. No significant changes were found in spontaneous motor activity, tail-flick response, but there was a decreased latency in passive avoidance test.
Vences-Mejía et al. 2006 [114] Biochemistry study of liver and brain detoxifying enzymes in rat 24 male Wistar rats (21 days old) were given by gavage Asp 75 and 125 mg/kg body weight daily for 30 days. Liver, cerebrum and cerebellum microsomes were assessed for activity of alkoxyresorufin O-dealkylase, 4-nitrophenol hydroxylase, erythromycin N –demethylase, and for different CytP450 isoforms by immunoblotting. 75 mg/kg Asp reliably increased the activity of all seven enzymes in the cerebrum and cerebellum, but not at the same levels.
Errico et al. 2008 [102] Behavioral, biochemistry, histology and electrophysiology study to assess the role of D-aspartate in regulating hippocampal synaptic plasticity Male wild-type and mutant C57Bl/6 mice with targeted homozygous deletion of the D-aspartate oxidase (Ddo-/-) gene were fed with D-aspartate 20 mM p.o. for 1 month. D-aspartate diet promoted long-term potentiation in hippocampal slices from both genetic and pharmacologically altered animal models, but it had no effect on the fundamental features of synaptic transmission; it slightly decreased spatial cognitive flexibility but not hippocampus-dependent learning and memory.
Free radicals production/oxidative stress
Mourad and Noor 2011 [90] Biochemistry study in rats Adult male Wistar albino rats (120-180 g) were given aspartame 40 mg/day p.o. for 2, 4 or 6 weeks, with equivalent control groups. Brain homogenate samples were subjected to biochemical tests. A significant decrease in lipid peroxidation occurred after 2 weeks of aspartame diet, followed by a significant increase after 4 weeks; reduced glutathione levels and increased superoxide dismutase activity were recorded after 4 and 6 weeks, while catalase activity increased after 6 weeks of aspartame diet.
Iyaswamy and Rathinasamy 2012 [88] Neurobiochemistry study in rats Male albino Wistar rats (200–220 g) were split in 3 groups: a saline control group, a methotrexate-treated control group, and a methotrexate-treated aspartame-fed group (75 mg/kg p.o. for 90 days on a folate-deficient diet). Aspartame induced a significant increase in lipid peroxidation, superoxide dismutase and catalase activity, decreased glutathione peroxidase activity, reduced glutathione and protein thiol levels, as well as detectable blood methanol levels.
Abdel-Salam et al. 2012 [85] Neurobiochemistry study in mice Male Swiss albino mice (20–22 g) were split into 10 groups: one saline control group (0.1 ml i.p.), 6 groups treated with lipopolysaccharide (LPS) 100 µg i.p. followed by aspartame 0, 0.625, 1.875, 5.625, 11.25, and 22.5 mg/kg s.c., and 3 groups treated with aspartame alone 11.25, 22.5, and 45 mg/kg s.c. Aspartame after LPS decreased lipid peroxidation, reduced glutathione (GSH) and nitrite concentrations in brain and liver. Aspartame alone increased lipid peroxidation, TNF-a and decreased GSH. Serotonin, noradrenaline, and dopamine in the brain were inhibited by aspartame in a dose-dependent manner. Nitrite, GSH, AST, ALT, ALP levels in the liver were not affected by aspartame. Oxidative stress and inflammation increased in the brain, but not in the liver.
Abhilash et al. 2013 [86] Neurobiochemistry and histopathology study in rats Three groups of male Wistar rats, (150–175 g) were created at random; the first group received aspartame 500 mg/kg in 3 ml water, the second group 1000 mg/kg, and the control group only 3 ml water daily for 180 days. The group that received 1000 mg/kg featured decreased brain concentrations of reduced glutathione (GSH) and glutathione reductase activity; the group fed with 500 mg/kg showed only a significant reduction in GSH. Histopathological examination revealed mild vascular congestion in the 1000 mg/kg group.
Prokić et al. 2014 [60] A study of oxidative status in erythrocytes of rats on aspartame diet There were two groups of animals: the experimental group received aspartame 40 mg/kg p.o. daily for 6 weeks, whereas the control group received only water. Superoxide anion, hydrogen peroxide, peroxynitrite and lipid peroxides concentrations were significantly higher in the erythrocytes of the aspartame-treated group. Reduced glutathione (GSH) levels and catalase activity both increased under aspartame treatment.
Iyyaswamy and Rathinasamy 2014 [89] Neurobiochemistry and histopathology study in rats Adult male Wistar albino rats (200–220 g) were divided into three groups: saline control, folate-deficient (methotrexate-treated), and folate-deficient treated with aspartame 40 mg/kg p.o. for 90 days. Subsequently brain samples and homogenates were obtained. Aspartame exposure led to significantly increased levels of protein carbonyl and decreased levels of protein thiol, increased lipid peroxidation, plasma methanol, and activity of superoxide dismutase, glutathione-S-transferase, glutathione peroxidase, catalase, significantly decreased levels of GSH, glutathione reductase. Proapoptotic gene expression was increased, as well as apoptosis markers caspase 3 and Bax, and CA1-3 pyramidal layer was depleted.
Choudhary and Rathinasamy 2014 [70] Neurobehavioral and oxidative stress study in rats Adult male Wistar albino rats (200-220 g) were fed a folate-deficient diet (FD) for 37 days and were given methotrexate (1 mg/kg) i.v. every second day for two weeks. The aspartame groups received aspartame 40 mg/kg/day p.o. 90 days. After 90 days of aspartame administration, there was no discernible change in motor behavior, but there was a considerable decrease in membrane-bound ATPase activity and a decline in both enzymatic and non-enzymatic antioxidant levels in spinal cord lysates.
Alkafafy et al. 2015 [87] Oxidative stress study on the rat liver 25 male Wistar albino rats aged 7 weeks were separated into 5 groups. The first 2 groups were given aspartame p.o. (250 and 1000 mg/kg), while groups 3-4 received saccharin (25 and 100 mg/kg, respectively), daily for 8 weeks. The aspartame-treated groups showed increased liver enzymes activities, decreased antioxidant levels; all sweetener-treated groups showed histological hepatotoxic effects, downregulation of the tumor suppressor gene P27 and overexpression of the main oncogene H-Ras, pointing to a possible risk of liver carcinogenesis.
Metabolic and other toxic effects
Abdel-Salam et al. 2009 [115] A study on protective effects of citric acid and aspartame against CCl4-induced hepatic injury in rats Adult Sprague-Dawley rats of both sexes (10 weeks, 120 g) were divided in 8 groups: 1 control group and 7 groups treated with CCl4 in olive oil (1:1 v/v) 2.8 mg/kg; these groups also received silymarin (25 mg/kg), aspartame (0.625 or 1.25 mg/kg), or citric acid (10 mg/kg, 100 mg/kg, or 1000 mg/kg) p.o. daily for 1 week. At 0.625 or 1.25 mg/kg, aspartame decreased plasma ALT, AST, and ALP, respectively, by 39.8–52.0%, 43.2–52.4%, and 50.0–68.5%. On histology, 1.25 mg/kg aspartame significantly decreased CCl4-induced vacuolar degeneration and necrosis.
Kim et al. 2011 [116] Behavioral, biochemistry and histopathology study on zebrafish

 Zebrafish were given a high-cholesterol diet (HCD) along with aspartame or saccharin (5.2% and 3.6% of total food weight) for 12 days. 30% of the aspartame-HCD group died (vs. 0% in the saccharin and control groups). The aspartame-fed group showed acute swimming defects, a significant rise in blood glucose (up to 125 mg/dl), with more inflammatory cells in brain and liver.
Choudhary and Rathinasamy 2016 [117]
 A study of expression of pro/antiapoptotic genes in immune organs of rats Male Wistar albino rats (200- 220 g) were fed a folate-deficient diet for 37 days, followed by methotrexate (MTX) every second day for two weeks; subsequently, they received aspartame 40 mg/kg/day (or saline in control) for 90 days. Aspartame treatment did not result in obvious DNA fragmentation in the spleen, thymus, or lymph nodes; it also did not significantly alter the mRNA levels of Bcl-2 and Bax in the immune organs, while Hsp70 expression increased significantly.
Gul et al. 2017 [118] A study of metabolic syndrome based on intestinal alkaline phosphatase inhibition by Phe 6-week old male mice fed a high-fat diet (HFD) or normal diet received aspartame in water (0.96 mg/ml) or regular water for 18 weeks. In an acute in vivo model, an intestinal pouch was created by isolating a 6-cm segment of small bowel and was injected with aspartame 34 mg/kg or control saline. In vitro experiments monitored alkaline phosphatase (ALP) activity in the presence or absence of regular or aspartame diet soda. Mice on HFD+aspartame gained more weight than the HFD+water group (48.1 vs. 42.4, p=0.0001), and showed a higher glucose intolerance (p=0.008); both HFD and normal diet+aspartame groups showed increased TNF-a levels. Aspartame lowered ALP activity in both in vivo and in vitro experiments (p=0.02 and p=0.034, respectively).
Helal et al. 2019 [119] Biochemistry study in rats 30 male albino rats (100-120 g) were fed for 30 days with aspartame (50 mg/kg), acesulfame-K (15 mg/kg) or control diet. Aspartame-treated rats had higher levels of serum glucose, insulin, creatinine, urea, lipid profiles (excepting HDL-C), higher ASAT and ALAT activities; serum testosterone, T3 and T4 levels decreased in the aspartame group, while total protein, albumin, and albumin/globulin ratio increased in both treated groups compared to control.
Nettleton et al. 2020 [120] Study of an obesogenic diet effects on metabolism, gut microbiota and mesolimbic reward system in rat dams and their offspring
 Following obesity induction, 150 female Sprague-Dawley rats were divided into three groups: 1. high fat/sucrose diet (HFS) + water (obese-WTR); 2. HFS + aspartame 5-7mg/kg/day (obese-APM); 3. HFS + stevia 2-3mg/kg/day (obese-STV). Infants were weaned onto a control diet and given water, then monitored for 18 weeks. Despite no direct low-calorie sweetener consumption by children, maternal low-calorie sweetener use together with HFS may affect weight management, glucose homeostasis, gut microbiota in dams and their offspring, particularly in early life. Mesolimbic reward pathway was altered in offspring of aspartame or stevia-fed dams: increased ventral tegmental area dopamine transporter and tyrosine hydroxylase (only group2) mRNA levels, increased nucleus accumbens D2 and mu opioid receptor levels.
Ragi et al. 2021 [11] Biochemistry and metabolism study in rats Adult male Sprague-Dawley rats (7-week-old) were given a 1-week adaption time, followed by aspartame (0.05% w/w) or sucralose (0.016% w/w) administration in diet, water, or both, for 7 weeks. Aspartame consumption considerably increased body weight and fat mass, mostly because of an improvement in energy efficiency. Rather than the method of intake, the impact was correlated with the dosage. Additionally, use of aspartame was linked to glucose intolerance.
Effects on immunity, inflammation, development
Pórtela et al. 2007 [77] A morphometric and kariometric study in pregnant rats 20 pregnant rats, distributed randomly in 4 groups, received either aspartame 14 mg/kg or control in water at normal temperature or 40°C; placentas, umbilical cords and fetal livers (1000 hepatocytes) were analyzed morphometrically by kariometry. The groups on aspartame at room temperature or 40°C showed reduced placental, maternal and fetal weight, umbilical cord length, as well as altered hepatocyte kariometric parameters.
Choudhary et al. 2014 [59] Biochemistry, oxidative stress and immune function study in rats Adult male Wistar albino rats (12 weeks of age, 200–220 g), fed a folate-deficient diet for 37 days followed by methotrexate 1 mg/kg i.v. every second day for 2 weeks, were treated with aspartame 40 mg/kg p.o. for 15, 30 and 90 days, followed by venous blood collection. In aspartame-fed groups there was a progressive decrease in RBC membrane-bound ATPase, G-6-PD and GR activity, increased lipid peroxidation and NO levels in RBC, neutrophils and lymphocytes, decreased neutrophil adhesion and phagocytic index, increased antibody titers and soluble immune complexes.
Shalaby et al. 2019 [78] Histological/immu-nohistochemical study of the placenta in rats 20 pregnant female rats received aspartame 14 mg/kg p.o. or control during days 9-11 of pregnancy. Aspartame treatment decreased placental weight and thickness of labyrinth and basal zones, induced rupture of interhemal membranes, lysis of trophoblast cells, as well as increased VEGF staining of labyrinth and basal zones.
Fareed and Mostafa
2021 [121]		 Biochemical and histological study on renal maturation in rat offspring
 Pregnant rats were randomly divided into four groups: 1.control group; 2.aspartame group: 40 mg/kg/day until postnatal day 30; 3.caffeine group: 80 mg/kg/day; 4.aspartame and caffeine group. Group 4 showed in kidneys a substantial increase in oxidative load (malondialdehyde), reduced antioxidant enzymes and total glutathione activity (superoxide dismutase and glutathione peroxidase). Renal tissues in group 4 matured faster than in groups 2 and 3, but with more pathological changes.
Genotoxic effects, mutagenic and carcinogenic potential
Bandyopadhyay et al. 2008 [122] Genotoxicity study by comet assay in the bone marrow cells of mice Swiss albino mice (8-10 weeks, 25 g) were orally administered aspartame (7, 14, 28, 35 mg/kg), acesulfame-K (150, 300, 600 mg/kg), and saccharin (50,
100, 200 mg/kg) individually. The animals were sacrificed after 18 h and the bone marrow cells were processed for comet assay.		 As evidenced by increased comet-tail extent and % DNA in the tail, sweetener-induced DNA strand breaks enhanced the comet characteristics of DNA in the bone marrow cells. Acesulfame-K and saccharin caused more DNA damage than aspartame.
Landrigan and Straif 2021 [19] Immunohistochemical and morphological reevaluation of a study performed at Ramazzini Institute in 2006-2007 on rats and mice with aspartame-induced tumors Reevaluation of studies BT6008 (aspartame 0-100000ppm since week 8 in rats), BT6009 (prenatal exposure in rats), BT6010 (prenatal exposure in Swiss mice) – a total of 2270 Sprague-Dawley rats and 852 Swiss mice. In 92.3% of cases, the immunohistochemical and morphological reevaluation supported the initial diagnosis of malignancy; 3 lesions were reclassified as lymphoid hyperplasia and three as chronic inflammation with fibrosis out of the 6 lesions originally identified as lymphomas (8% of all HLTs). No signs of Mycoplasma infection were seen.
In vitro studies
Neurological effects
Fountain et al. 1988 [123] In vitro study of hippocampal slice excitability and long-term potentiation (LTP) Female Long-Evans rats aged 60–90 days used to prepare 400–450 µm thick hippocampal slices. Exposure to 0.01, 0.1, 1, and 10 mM aspartame potentiated the electrical response of CA1 neurons (increased fEPSP slope and amplitude), similar to 0.1 mM aspartate, phenylalanine or its methyl ester, without effects on inhibitory systems (tested by double-pulse protocols) and LTP.
Pan-Hou et al. 1990 [84] Ligand-receptor binding assay Binding of NMDA, aspartate and aspartame in competition with 3H-glutamate on NMDARs from rat brain synaptic membrane preparations. 0.1 mM NMDA, 1 mM aspartate and 1 mM aspartame displaced >50% of 3H-glutamate without modifying Vmax of glutamate binding, suggesting competitive binding.
Simintzi et al. 2007a [124] Acetylcholine esterase activity in rat hippocampus and that of pure enzyme Rat hippocampus homogenates or pure AChE enzyme were incubated with aspartame metabolites (aspartate 0.82-10 mM, phenylalanine 0.07-0.5 mM, methanol 0-0.8 mM). Reduced AChE activity at high doses of metabolites (equivalent to consumption of aspartame 150-200 mg/kg).
Simintzi et al. 2007b [92] Na/K ATPase activity in rat hippocampus and that of pure enzyme Rat hippocampus homogenates or pure Na/K ATPase were incubated with aspartame metabolites (aspartate 0.82-10 mM, phenylalanine 0.07-0.5 mM, methanol 0-0.8 mM) Reduced Na/K ATPase activity in homogenates (but increased activity of pure enzyme) at higher doses of metabolites (equivalent to consumption of aspartame 34-200 mg/kg).
Cytotoxic, genotoxic and carcinogenic effects
Kashanian et al. 2013 [125] DNA binding study Native calf thymus DNA interaction with aspartame at physiological pH was studied by spectrophotometry, spectrofluorimetric competition and circular dichroism; aspartame fluorescence quenching by DNA at various temperatures was used to estimate the number of binding sites per base pair. The UV absorption band of aspartame exhibits hypochromism and red shift. Fluorescence quenching by DNA provided binding constants and corresponding number of binding sites; enthalpy (+181 kJ/mol) and entropy (+681 J/mol·K) changes were estimated. Iodide, methylene blue and competitive Hoechst 22358-aspartame quenching experiments proved minor groove DNA binding of aspartame, and lack of CD spectra changes with aspartame indicate a non-intercalative interaction.
Pandurangan et al. 2015 [74]
 Cytotoxicity study on human cervical carcinoma cells
 HeLa cells were seeded at a density of 2.2 x 105 cells/well in 6-well plates. After 24 h, the cells were treated with aspartame at different concentrations (10 µM, 100 µM, 1 mM, 10 mM, 20 mM) for 24 and 48 h. After exposure to greater aspartame concentrations, cell viability was considerably changed. At greater aspartame exposure doses, ROS produced by mitochondria increased. DNA fragmentation occurred upon exposure to aspartame 10 or 20 mM. At 1–20 mM aspartame concentrations, apoptotic and necrotic bodies were discovered.
Park et al. 2019 [96] Cytotoxicity study on embryonic mouse hypothalamic cell line mHypoE-N43/5 mHypoE-N43/5 cells were cultured in medium containing either vehicle (saline) or 0.5, 5, 10, 20 mM of sucralose, aspartame, acesulfame-K, or rebaudioside A (all from Sigma) for 48 h. All non-nutritive sweetener stock solutions were made in sterile water. When given in tolerable amounts for daily consumption, rebaudioside A did not cause ER stress, but sucralose, aspartame, and acesulfame-K did. Arcuate nucleus explants axon outgrowth was unaffected by sucralose, aspartame, or rebaudioside A, and aspartame had no impact on caspase 3/7 activity.
Maghiari et al. 2020 [66]
 Cytotoxicity study on HT-29 human colorectal carcinoma cells and chicken egg embryos
 HT-29 human colorectal carcinoma cells were cultured in specific medium, and incubated with different concentrations of aspartame (0.1, 0.25, 0.5, 1, 3, 6, 15, 30, or 50 mM) for 72 h, followed by Alamar blue cell viability assay. Chorioallantoic membranes of eggs were exposed to 10 µl aspartame solution placed inside a ring. At the highest aspartame doses examined (15, 30 and 50 mM), there was a dose-dependent cytotoxic effect with a considerable reduction in viable cells, as well as morphological cellular alterations. Aspartame (15 and 30 mM) was shown to have a pro-angiogenic effect in ovo as well as a negligible irritating potential.
Çadirci et al. 2020 [126]

 An in vitro cytotoxicity, genotoxicity and oxidative stress study on cultured human blood cells

 Cytotoxicity was studied via MTT and lactate dehydrogenase release tests, genotoxic damage potential by using chromosome aberration (CA) assay, and antioxidant/oxidant activity by using total antioxidant capacity (TAC) and total oxidative stress analysis in cultured primary human whole blood cells. Substantial, clearly concentration-dependent declines in cell viability were obtained upon aspartame exposure (3.125-100 mg/l). In aspartame-treated cells there was an increase in the frequency of CA, while TAC and TOS levels in whole blood cultures were not significantly altered.
Griebsch et al. 2023 [61] Oxidative stress, membrane composition and mitochondrial damage study The SH-SY5Y human neuroblastoma cell line was exposed to aspartame (271.7 μM) or its metabolites (Asp, Phe, methanol) Aspartame and metabolites treatment altered mitochondiral integrity (assessed by transmission electron microscopy), increased total mitochondrial and lipid droplets area, decreased cardioliin levels to 56.7±5.6% (p=0.011), activated mitophagy and ROS release, increased expression of FIS1, PINK1, SOD1 and 2, increase in 7 triacylglycerol, phosphatidylcholine and phosphatidylethanolamine species
Angiogenesis effects
Alleva et al. 2011 [67] In vitro angiogenesis and cytotoxicity study Human endothelial cells were co-cultured with fibroblasts in a standardized angiogenesis model (Angio-Kit). Human umbilical vein endothelial cells (HUVEC) and fibroblasts were cultured in vitro. All cultures were exposed to aspartame 20, 40, 60, 80, or 100 µM dissolved in complete culture medium. Exposure to aspartame stimulated angiogenesis, and also ROS production in endothelial cells associated with cytotoxicity (increased Erk1/2 and p38 activation and IL-6 secretion), but not in IMR-90 fibroblasts.
Yesildal et al. 2015 [69] In vitro and in vivo angiogenesis and wound healing study Male Sprague Dawley rats (8 weeks, 200–250 g) were used to remove two circular slices of skin (5 mm diameter). The wounds were treated with PBS or aspartame 50 mM for 7 days and collected on day 8, after calculating the surface area. Chicken eggs choriallantoic membrane (CAM) angiogenesis was tested by application of aspartame 6-60 mM, and HUVEC cells exposed to aspartame 20-100 µM were used for tube formation and 2,3-bis-2H-tetrazolium-5-carboxanilide (XTT) viability assays. Aspartame increased CAM angiogenesis in a dose-dependent manner (p<0.001) and improved wound healing (p<0.05). Aspartame also slightly increased HUVEC cell proliferation (not statistically significant) and had no effect on tube formation.
Enuwosa et al. 2021 [68] In vitro study of effects of artificial sweeteners on VEGF-induced permeability of glomerular endothelium
 Human primary glomerular microvascular endothelial cells (GMVEC) in culture were treated with increasing concentrations (0.1-100 µM) of aspartame, saccharin, and sucralose for 24 h, and tested for endothelial monolayer permeability with dextran 20kDa-FITC upon VEGF exposure, VE-cadherin expression and intracellular cAMP level by ELISA, ROS production, and GC-MS for sucralose concentration in cell lysates. All tested sweeteners had no effect on traditional VEGF signaling, but only saccharin and sucralose protected against VEGF-induced permeability, dependent on the sweet taste receptor T1R3. VEGF induced an increase in ROS production, which was not influenced by any sweetener. All sweeteners maintained VE-cadherin expression during VEGF exposure. In the absence of VEGF, aspartame significantly increased oxidative stress in GMVEC, while sucralose and saccharin had no effect.
Other effects
Manion et al. 2001 [127] In vitro and clinical study of the efficacy of aspartame in treating sickle cell anemia Twenty children with sickle cell anemia provided heparinized blood samples exposed to aspartame 1 or 2 mg/mL. 23 other patients with homozygous/heterozygous HbS or HbS/b0 were given aspartame 1.5, 3 or 6 mg/kg single-dose, and their blood samples were monitored up to 1440 min afterwards. 1 mg/mL reduced sickled cells from 28% to 14%, and even further with 2 mg/mL. In 15 individuals with HbSS anemia, sickling was prevented by 6 mg/kg aspartame for at least 6 hours.
Rios et al. 2018 [128] Comparison of enamel erosion produced by regular and light colas, with addition of aspartame sweetener
 60 bovine enamel blocks were exposed 2 min. 4 times daily for 5 consecutive days to erosion in 5 varieties of cola and kept in artificial saliva between exposures. Experimental groups: RC-regular cola-degassed (pH 2.6), RCpH-a base was added to raise the pH of RC (pH 3.0), RCAS aspartame added to RC (pH 2.6), LC-light cola (pH 3.0), LCpH-acid added to LC (pH 2.6). The % surface hardness change of enamel after 1 day was similar for all 5 groups. LC caused less enamel loss than RC, but differences were not significant (p>.05) between erosion and erosion plus abrasion for LC. However, for RC erosion plus abrasion resulted in higher enamel loss than erosion alone. LCpH had an erosion effect similar to RC, while RCpH had similar effect to LC.
Pandurangan et al. 2014 [129] An in vitro study of aspartame effects on preadipocyte differentiation 3T3-L1 mouse preadipocytes were cultured and differentiated for 6 days in the absence and presence of aspartame 10 μg/ml. The induction of p-PPARg, PPARg, SREBP1, and adipsin (by Western blot) and PPARγ, FABP4, and C/EBPα (RT-qPCR) was significantly reduced in aspartame-treated preadipocytes, as well as lipid accumulation (by Oil Red O staining).
Sun et al. 2019 [130]
 In vivo and in vitro study on small intestinal cell cycle and stimulating secretion and expression of glucagon-like peptide −2 (GLP-2) in pre-weaned lambs Twelve 14-day lambs were randomly divided into two groups; control (n=6) fed on starter food, and aspartame-fed (200 mg/kg) (n=6) up to 49 days. At 56 days, 4 healthy lambs' jejunal tissue was used to dissociate and culture epithelial cells, treated with control, GLP-2 10 nM alone or with IGF-1R inhibitor picropodophyllin (PPP) 1 µM. Aspartame-fed lambs showed higher GLP-2 plasma concentrations (p <.05), and larger jejunum weight/live body weight and jejunal crypt depth, as well as increased expression of cyclins D1, A2, CDK4 and 6, glucagon, IGF-1, GLP-2R in jejunum/ileum. Jejunal cells treated with GLP-2 (2h) showed increased proliferation (MTT test) and expression of IGF-1, cyclin D1, CDK6, which were decreased by PPP.
Chontzopoulou et al. 2021 [131] In silico and experimental study on lipoxygenase (LOX) inhibition Different LOX isoforms crystal structures were used for in silico studies: docking, molecular dynamics (MD) followed by QM/MM geometry optimization of ligand-receptor complexes. For in vitro assays of saturation transfer difference NMR (STD-NMR), a stock solution (10 mM) of the tested compound was prepared in DMSO. In silico and in vitro assays confirmed strong aspartame binding to LOX-1 isoform (IC50=50 ± 3.0 μΜ) with functional inhibition. These results suggest that aspartame could serve as a novel starting point for drug design of LOX inhibitors.

References

  1. Chattopadhyay, S.; Raychaudhuri, U.; Chakraborty, R. Artificial sweeteners - a review. J Food Sci Technol 2014, 51, 611–621. [Google Scholar] [PubMed]
  2. Marinovich, M.; Galli, C.L.; Bosetti, C.; Gallus, S.; La Vecchia, C. Aspartame, low-calorie sweeteners and disease: regulatory safety and epidemiological issues. Food Chem Toxicol 2013, 60, 109–115. [Google Scholar]
  3. Mazur, R.H. Discovery of aspartame. In Aspartame: Physiology and Biochemistry, Stegink, L.D., Filer, L.J.J., Eds.; Marcel Dekker: New York, 1984; pp. 3–9. [Google Scholar]
  4. Mazur, R.H.; Schlatter, J.M.; Goldkamp, A.H. Structure-taste relationships of some dipeptides. J Am Chem Soc 1969, 91, 2684–2691. [Google Scholar]
  5. Tobey, N.A.; Heizer, W.D. Intestinal hydrolysis of aspartylphenylalanine--the metabolic product of aspartame. Gastroenterology 1986, 91, 931–937. [Google Scholar]
  6. Barceloux, D.G.; Bond, G.R.; Krenzelok, E.P.; Cooper, H.; Vale, J.A. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol 2002, 40, 415–446. [Google Scholar]
  7. EFSA Panel on Food Additives Nutrient Sources added to Food. Scientific Opinion on the re-evaluation of aspartame (E 951) as a food additive. EFSA Journal 2013, 12, 3696. [Google Scholar]
  8. Soffritti, M.; Belpoggi, F.; Degli Esposti, D.; Lambertini, L.; Tibaldi, E.; Rigano, A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect 2006, 114, 379–385. [Google Scholar]
  9. Soffritti, M.; Belpoggi, F.; Tibaldi, E.; Esposti, D.D.; Lauriola, M. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environ Health Perspect. 2007, 115, 1293–1297. [Google Scholar]
  10. Collison, K.S.; Inglis, A.; Shibin, S.; Andres, B.; Ubungen, R.; Thiam, J.; Mata, P.; Al-Mohanna, F.A. Differential effects of early-life NMDA receptor antagonism on aspartame-impaired insulin tolerance and behavior. Physiol Behav 2016, 167, 209–221. [Google Scholar]
  11. Ragi, M.E.; El-Haber, R.; El-Masri, F.; Obeid, O.A. The effect of aspartame and sucralose intake on body weight measures and blood metabolites: role of their form (solid and/or liquid) of ingestion. Br J Nutr 2021, 128, 1–9. [Google Scholar]
  12. Sykes, M. The Aspartame Controversy of 1981, The Hidden Truth Behind the Not-So-Sweet Artificial Sweetner. 2015.
  13. Butchko, H.; Stargel, W.; Comer, C.; Mayhew, D.; Benninger, C.; Blackburn, G.; De Sonneville, L.; Geha, R.; Hertelendy, Z.; Kostner, A. Intake of aspartame vs the acceptable daily intake. Regul Toxicol Pharmacol 2002, 35, S13–S16. [Google Scholar]
  14. Fatibello-Filho, O.; Marcolino-Junior, L.H.; Pereira, A.V. Solid-phase reactor with copper (II) phosphate for flow-injection spectrophotometric determination of aspartame in tabletop sweeteners. Anal Chim Acta 1999, 384, 167–174. [Google Scholar]
  15. Fitch, C.; Keim, K. Position of the academy of nutrition and dietetics: use of nutritive and nonnutritive sweetener. J Acad Nutr Diet 2012, 112, 739–758. [Google Scholar]
  16. Monte, W.C. Aspartame: methanol and the public health. In Proceedings of the J Appl Nutr; 1984. [Google Scholar]
  17. Magnuson, B.A.; Burdock, G.A.; Doull, J.; Kroes, R.M.; Marsh, G.M.; Pariza, M.W.; Spencer, P.S.; Waddell, W.J.; Walker, R.; Williams, G.M. Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies. Crit Rev Toxicol 2007, 37, 629–727. [Google Scholar]
  18. National Research Council. Pesticides in the Diets of Infants and Children; The National Academies Press: Washington DC, 1993. [Google Scholar]
  19. Landrigan, P.J.; Straif, K. Aspartame and cancer - new evidence for causation. Environ Health 2021, 20, 42. [Google Scholar]
  20. Olney, J.W.; Farber, N.B.; Spitznagel, E.; Robins, L.N. Increasing brain tumor rates: is there a link to aspartame? J Neuropathol Exp Neurol 1996, 55, 1115–1123. [Google Scholar] [CrossRef]
  21. Czarnecka, K.; Pilarz, A.; Rogut, A.; Maj, P.; Szymańska, J.; Olejnik, Ł.; Szymański, P. Aspartame-True or False? Narrative Review of Safety Analysis of General Use in Products. Nutrients 2021, 13, 1957. [Google Scholar]
  22. Amchra, F.Z.; Al Faiz, C.; Chaouqi, S.; Khiraoui, A.; Benhmimou, A.; Guedira, T. Effect of Stevia rebaudiana, sucrose and aspartame on human health: A comprehensive review. Journal of Medicinal Plants Studies 2018, 6, 102–108. [Google Scholar]
  23. Singh, M.; Kumar, A.; Tarannum, N. Water-compatible 'aspartame'-imprinted polymer grafted on silica surface for selective recognition in aqueous solution. Anal Bioanal Chem 2013, 405, 4245–4252. [Google Scholar]
  24. Bell, L.N.; Labuza, T.P. Aspartame degradation kinetics as affected by pH in intermediate and low moisture food systems. Journal of food science 1991, 56, 17–20. [Google Scholar]
  25. Lipton, W.E.; Li, Y.N.; Younoszai, M.K.; Stegink, L.D. Intestinal absorption of aspartame decomposition products in adult rats. Metabolism 1991, 40, 1337–1345. [Google Scholar]
  26. Magnuson, B.A.; Carakostas, M.C.; Moore, N.H.; Poulos, S.P.; Renwick, A.G. Biological fate of low-calorie sweeteners. Nutr Rev 2016, 74, 670–689. [Google Scholar] [PubMed]
  27. Hooper, N.M.; Hesp, R.J.; Tieku, S. Metabolism of aspartame by human and pig intestinal microvillar peptidases. Biochem J 1994, 298, 635–639. [Google Scholar] [CrossRef] [PubMed]
  28. Li, D.; Zhao, X.H.; Yang, T.B.; Johnson, E.W.; Thacker, P.A. A comparison of the intestinal absorption of amino acids in piglets when provided in free form or as a dipeptide. Asian-Aus J Anim Sci 1999, 12, 939–943. [Google Scholar]
  29. Adibi, S.A. Intestinal transport of dipeptides in man: relative importance of hydrolysis and intact absorption. J Clin Invest 1971, 50, 2266–2275. [Google Scholar]
  30. Stegink, L.D. The aspartame story: a model for the clinical testing of a food additive. Am J Clin Nutr 1987, 46, 204–215. [Google Scholar]
  31. Stegink, L.D.; Brummel, M.C.; Filer, L.J., Jr.; Baker, G.L. Blood methanol concentrations in one-year-old infants administered graded doses of aspartame. J Nutr 1983, 113, 1600–1606. [Google Scholar]
  32. Stegink, L.D.; Brummel, M.C.; McMartin, K.; Martin-Amat, G.; Filer, L.J., Jr.; Baker, G.L.; Tephly, T.R. Blood methanol concentrations in normal adult subjects administered abuse doses of aspartame. J Toxicol Environ Health 1981, 7, 281–290. [Google Scholar]
  33. Stegink, L.D.; Filer Jr, L. Effects of Aspartame Ingestion on Plasma Aspartate, Phenylalanine and Methanol Concentrations in Potentially Sensitive Populations. In The clinical evaluation of a food additive: Assessment of aspartame; Tschanz, C., Butchko, H.H., Stargel, W., Kotsonis, F.N., Eds.; CRC Press: Boca Raton, 1996; pp. 87–113. [Google Scholar]
  34. Stegink, L.D.; Filer, L.J., Jr.; Baker, G.L. Plasma amino acid concentrations in normal adults ingesting aspartame and monosodium L-glutamate as part of a soup/beverage meal. Metabolism 1987, 36, 1073–1079. [Google Scholar]
  35. Stegink, L.D.; Filer, L.J., Jr.; Baker, G.L. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults. Metabolism 1988, 37, 246–251. [Google Scholar]
  36. Stegink, L.D.; Filer, L.J., Jr.; Baker, G.L.; Brummel, M.C. Plasma and erythrocyte amino acid levels of adult humans given 100 mg/kg body weight aspartame. Toxicology 1979, 14, 131–140. [Google Scholar] [PubMed]
  37. Stegink, L.D.; Filer, L.J., Jr.; Baker, G.L.; McDonnell, J.E. Effect of an abuse dose of aspartame upon plasma and erythrocyte levels of amino acids in phenylketonuric heterozygous and normal adults. J Nutr 1980, 110, 2216–2224. [Google Scholar] [PubMed]
  38. Stegink, L.D.; Filer, L.J., Jr.; Bell, E.F.; Ziegler, E.E.; Tephly, T.R. Effect of repeated ingestion of aspartame-sweetened beverage on plasma amino acid, blood methanol, and blood formate concentrations in normal adults. Metabolism 1989, 38, 357–363. [Google Scholar] [PubMed]
  39. Stegink, L.D.; Lindgren, S.D.; Brummel, M.C.; Stumbo, P.J.; Wolraich, M.L. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. Am J Clin Nutr 1995, 62, 1206–1211. [Google Scholar] [PubMed]
  40. Koehler, S.M.; Glaros, A. The effect of aspartame on migraine headache. Headache 1988, 28, 10–14. [Google Scholar] [CrossRef]
  41. Newman, L.C.; Lipton, R.B. Migraine MLT-down: an unusual presentation of migraine in patients with aspartame-triggered headaches. Headache 2001, 41, 899–901. [Google Scholar]
  42. Schiffman, S.S.; Buckley, C.E., 3rd; Sampson, H.A.; Massey, E.W.; Baraniuk, J.N.; Follett, J.V.; Warwick, Z.S. Aspartame and susceptibility to headache. N Engl J Med 1987, 317, 1181–1185. [Google Scholar]
  43. Van den Eeden, S.K.; Koepsell, T.D.; Longstreth, W.T., Jr.; van Belle, G.; Daling, J.R.; McKnight, B. Aspartame ingestion and headaches: a randomized crossover trial. Neurology 1994, 44, 1787–1793. [Google Scholar] [CrossRef]
  44. Walton, R.G.; Hudak, R.; Green-Waite, R.J. Adverse reactions to aspartame: double-blind challenge in patients from a vulnerable population. Biol Psychiatry 1993, 34, 13–17. [Google Scholar] [CrossRef]
  45. Ranney, R.E.; Oppermann, J.A. A review of the metabolism of the aspartyl moiety of aspartame in experimental animals and man. J Environ Pathol Toxicol 1979, 2, 979–985. [Google Scholar]
  46. Shaywitz, B.A.; Sullivan, C.M.; Anderson, G.M.; Gillespie, S.M.; Sullivan, B.; Shaywitz, S.E. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics 1994, 93, 70–75. [Google Scholar] [CrossRef]
  47. Choudhary, A.K.; Lee, Y.Y. The debate over neurotransmitter interaction in aspartame usage. J Clin Neurosci 2018, 56, 7–15. [Google Scholar] [PubMed]
  48. Humphries, P.; Pretorius, E.; Naudé, H. Direct and indirect cellular effects of aspartame on the brain. Eur J Clin Nutr 2008, 62, 451–462. [Google Scholar] [PubMed]
  49. Reinhard, J.F.; Reinhard, J.F.J. Experimental evaluation of anticonvulsants. In Anticonvulsants, Vida, J.A., Ed.; Academic Press: New York, 1972; pp. 58–110. [Google Scholar]
  50. Maher, T.J.; Wurtman, R.J. Possible neurologic effects of aspartame, a widely used food additive. Environ Health Perspect 1987, 75, 53–57. [Google Scholar] [CrossRef]
  51. Iyaswamy, A.; Kammella, A.K.; Thavasimuthu, C.; Wankupar, W.; Dapkupar, W.; Shanmugam, S.; Rajan, R.; Rathinasamy, S. Oxidative stress evoked damages leading to attenuated memory and inhibition of NMDAR-CaMKII-ERK/CREB signalling on consumption of aspartame in rat model. J Food Drug Anal 2018, 26, 903–916. [Google Scholar] [PubMed]
  52. Nelson, D.L.; Cox, M.M. Lehninger principles of biochemistry, 5th edition ed.; WH Freeman & Co.: New York, 2008. [Google Scholar]
  53. Rycerz, K.; Jaworska-Adamu, J.E. Effects of aspartame metabolites on astrocytes and neurons. Folia Neuropathol 2013, 51, 10–17. [Google Scholar] [CrossRef]
  54. Ardalan, M.R.; Tabibi, H.; Attari, V.E.; Mahdavi, A.M. Nephrotoxic effect of aspartame as an artificial sweetener: A brief review. Iranian J Kidney Dis 2017, 11, 339. [Google Scholar]
  55. Debras, C.; Chazelas, E.; Sellem, L.; Porcher, R.; Druesne-Pecollo, N.; Esseddik, Y.; de Edelenyi, S.F.; Agaësse, C.; De Sa, A.; Lutchia, R.; et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 2022, 378, e071204. [Google Scholar]
  56. Alwaleedi, S.A. Alterations in antioxidant defense system in hepatic and renal tissues of rats following aspartame intake. J Appl Biol Biotechnol 2016, 4, 0–5. [Google Scholar]
  57. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine (5th edn.); Oxford University Press: 2015; p. 896.
  58. Anbara, H.; Kian, M.; Darya, G.H.; Sheibani, M.T. Long-term intake of aspartame-induced cardiovascular toxicity is reflected in altered histochemical parameters, evokes oxidative stress, and trigger P53-dependent apoptosis in a mouse model. Int J Exp Pathol 2022, 103, 252–262. [Google Scholar]
  59. Choudhary, A.K.; Rathinasamy, S.; Sundareswaran, L. Role of antioxidant enzymes in oxidative stress and immune response evaluation of aspartame in blood cells of wistar albino rats. Int Food Res J (Malaysia) 2014, 21, 2263–2272. [Google Scholar]
  60. Prokić, M.D.; Paunović, M.G.; Matić, M.M.; Djordjević, N.Z.; Ognjanović, B.I.; Štajn, A.S.; Saičić, Z.S. Prooxidative effects of aspartame on antioxidant defense status in erythrocytes of rats. J Biosci 2014, 39, 859–866. [Google Scholar] [PubMed]
  61. Griebsch, L.V.; Theiss, E.L.; Janitschke, D.; Erhardt, V.K.J.; Erhardt, T.; Haas, E.C.; Kuppler, K.N.; Radermacher, J.; Walzer, O.; Lauer, A.A.; et al. Aspartame and its metabolites cause oxidative stress and mitochondrial and lipid alterations in SH-SY5Y cells. Nutrients 2023, 15, 1467. [Google Scholar]
  62. Maslova, E.; Strøm, M.; Olsen, S.F.; Halldorsson, T.I. Consumption of artificially-sweetened soft drinks in pregnancy and risk of child asthma and allergic rhinitis. PLoS One 2013, 8, e57261. [Google Scholar]
  63. Bassett, J.K.; Milne, R.L.; English, D.R.; Giles, G.G.; Hodge, A.M. Consumption of sugar-sweetened and artificially sweetened soft drinks and risk of cancers not related to obesity. Int J Cancer 2020, 146, 3329–3334. [Google Scholar] [PubMed]
  64. Debras, C.; Chazelas, E.; Srour, B.; Druesne-Pecollo, N.; Esseddik, Y.; de Edelenyi, S.F.; Agaësse, C.; De Sa, A.; Lutchia, R.; Gigandet, S.; et al. Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study. PLoS Med 2022, 19, e1003950. [Google Scholar]
  65. Schernhammer, E.S.; Bertrand, K.A.; Birmann, B.M.; Sampson, L.; Willett, W.C.; Feskanich, D. Consumption of artificial sweetener- and sugar-containing soda and risk of lymphoma and leukemia in men and women. Am J Clin Nutr 2012, 96, 1419–1428. [Google Scholar]
  66. Maghiari, A.L.; Coricovac, D.; Pinzaru, I.A.; Macașoi, I.G.; Marcovici, I.; Simu, S.; Navolan, D.; Dehelean, C. High Concentrations of Aspartame Induce Pro-Angiogenic Effects in Ovo and Cytotoxic Effects in HT-29 Human Colorectal Carcinoma Cells. Nutrients 2020, 12, 3600. [Google Scholar]
  67. Alleva, R.; Borghi, B.; Santarelli, L.; Strafella, E.; Carbonari, D.; Bracci, M.; Tomasetti, M. In vitro effect of aspartame in angiogenesis induction. Toxicol In Vitro 2011, 25, 286–293. [Google Scholar]
  68. Enuwosa, E.; Gautam, L.; King, L.; Chichger, H. Saccharin and sucralose protect the glomerular microvasculature in vitro against VEGF-induced permeability. Nutrients 2021, 13, 2746. [Google Scholar]
  69. Yesildal, F.; Aydin, F.N.; Deveci, S.; Tekin, S.; Aydin, I.; Mammadov, R.; Fermanli, O.; Avcu, F.; Acikel, C.H.; Ozgurtas, T. Aspartame induces angiogenesis in vitro and in vivo models. Hum Exp Toxicol 2015, 34, 260–265. [Google Scholar] [CrossRef] [PubMed]
  70. Choudhary, A.K.; Rathinasamy, S. Effect of aspartame in spinal cord and motor behavior in Wistar albino rats. J Behav Health 2014, 3, 107–111. [Google Scholar] [CrossRef]
  71. Choudhary, A.K.; Pretorius, E. Revisiting the safety of aspartame. Nutr Rev 2017, 75, 718–730. [Google Scholar] [CrossRef] [PubMed]
  72. Liu, L.; Zhang, P.; Wang, Y.; Cui, W.; Li, D. The relationship between the use of artificial sweeteners and cancer: A meta-analysis of case-control studies. Food Sci Nutr 2021, 9, 4589–4597. [Google Scholar] [CrossRef] [PubMed]
  73. Guercio, B.J.; Zhang, S.; Niedzwiecki, D.; Li, Y.; Babic, A.; Morales-Oyarvide, V.; Saltz, L.B.; Mayer, R.J.; Mowat, R.B.; Whittom, R. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PloS one 2018, 13, e0199244. [Google Scholar] [CrossRef]
  74. Pandurangan, M.; Enkhtaivan, G.; Mistry, B.; Chandrasekaran, M.; Noorzai, R.; Kim, D.H. Investigation of role of aspartame on apoptosis process in HeLa cells -->. Saudi J Biol Sci 2016, 23, 503–506. [Google Scholar] [CrossRef]
  75. Schiano, C.; Grimaldi, V.; Franzese, M.; Fiorito, C.; De Nigris, F.; Donatelli, F.; Soricelli, A.; Salvatore, M.; Napoli, C. Non-nutritional sweeteners effects on endothelial vascular function. Toxicology in Vitro 2020, 62, 104694. [Google Scholar] [CrossRef]
  76. Pandurangan, M.; Enkhtaivan, G.; Kim, D.H. Cytotoxic effects of aspartame on human cervical carcinoma cells. Toxicol Res (Camb) 2016, 5, 45–52. [Google Scholar] [CrossRef]
  77. Pórtela, G.S.; Azoubel, R.; Batigália, F. Effects of aspartame on maternal-fetal and placental weights, length of umbilical cord and fetal liver: a kariometric experimental study. Int J Morphol 2007, 25, 549–554. [Google Scholar] [CrossRef]
  78. Shalaby, A.M.; Ibrahim, M.; Aboregela, A.M. Effect of aspartame on the placenta of adult albino rat. A histological and immunohistochemical study. Ann Anat 2019, 224, 133–141. [Google Scholar] [CrossRef]
  79. Reiner, A.; Levitz, J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron 2018, 98, 1080–1098. [Google Scholar] [CrossRef] [PubMed]
  80. Polizzi, S.; Pira, E.; Ferrara, M.; Bugiani, M.; Papaleo, A.; Albera, R.; Palmi, S. Neurotoxic effects of aluminium among foundry workers and Alzheimer’s disease. Neurotoxicology 2002, 23, 761–774. [Google Scholar] [CrossRef] [PubMed]
  81. Olney, J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969, 164, 719–721. [Google Scholar] [CrossRef] [PubMed]
  82. Olney, J.W. Excitotoxic food additives--relevance of animal studies to human safety. Neurobehav Toxicol Teratol 1984, 6, 455–462. [Google Scholar]
  83. Choudhary, A.K.; Lee, Y.Y. Neurophysiological symptoms and aspartame: What is the connection? Nutr Neurosci 2017, 21, 306–316. [Google Scholar] [CrossRef]
  84. Pan-Hou, H.; Suda, Y.; Ohe, Y.; Sumi, M.; Yoshioka, M. Effect of aspartame on N-methyl-D-aspartate-sensitive L-[3H] glutamate binding sites in rat brain synaptic membranes. Brain Res 1990, 520, 351–353. [Google Scholar] [CrossRef]
  85. Abdel-Salam, O.M.; Salem, N.A.; Hussein, J.S. Effect of aspartame on oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated mice. Neurotoxicity research 2012, 21, 245–255. [Google Scholar] [CrossRef]
  86. Abhilash, M.; Sauganth Paul, M.; Varghese, M.V.; Nair, R.H. Long-term consumption of aspartame and brain antioxidant defense status. Drug Chem Toxicol 2013, 36, 135–140. [Google Scholar] [CrossRef]
  87. Alkafafy, M.E.-S.; Ibrahim, Z.S.; Ahmed, M.M.; El-Shazly, S.A. Impact of aspartame and saccharin on the rat liver: Biochemical, molecular, and histological approach. Int J Immunopathol Pharmacol 2015, 28, 247–255. [Google Scholar] [CrossRef]
  88. Iyaswamy, A.; Rathinasamy, S. Effect of chronic exposure to aspartame on oxidative stress in the brain of albino rats. J Biosci 2012, 37, 679–688. [Google Scholar] [CrossRef]
  89. Iyaswamy, A.; Rathinasamy, S. Biochemical responses and mitochondrial mediated activation of apoptosis on long-term effect of aspartame in rat brain. Redox Biol 2014, 2, 820–831. [Google Scholar]
  90. Mourad, I.M.; Noor, N.A. Aspartame (a widely used artificial sweetener) and oxidative stress in the rat cerebral cortex. Int J Pharm Biomed Sci 2011, 2, 4–10. [Google Scholar]
  91. Christian, B.; McConnaughey, K.; Bethea, E.; Brantley, S.; Coffey, A.; Hammond, L.; Harrell, S.; Metcalf, K.; Muehlenbein, D.; Spruill, W. Chronic aspartame affects T-maze performance, brain cholinergic receptors and Na+, K+-ATPase in rats. Pharmacol Biochem Behav 2004, 78, 121–127. [Google Scholar] [CrossRef] [PubMed]
  92. Simintzi, I.; Schulpis, K.H.; Angelogianni, P.; Liapi, C.; Tsakiris, S. L-Cysteine and glutathione restore the reduction of rat hippocampal Na+, K+-ATPase activity induced by aspartame metabolites. Toxicology 2007, 237, 177–183. [Google Scholar] [CrossRef] [PubMed]
  93. Lipton, S.A.; Choi, Y.-B.; Sucher, N.J.; Chen, H.-S.V. Neuroprotective versus neurodestructive effects of NO-related species. Biofactors 1998, 8, 33–40. [Google Scholar] [CrossRef] [PubMed]
  94. Yoshikawa, T.; Naito, Y. What is oxidative stress ? Japan Medical Association Journal 2000, 124, 1549–1553. [Google Scholar]
  95. Iyaswamy, A.; Rathinasamy, S. Neurobehavioral changes and activation of neurodegenerative apoptosis on long-term consumption of aspartame in the rat brain. J Nutr Intermed Metabol 2015, 2, 76–85. [Google Scholar]
  96. Park, S.; Sethi, S.; Bouret, S.G. Non-nutritive Sweeteners Induce Hypothalamic ER Stress Causing Abnormal Axon Outgrowth. Front Endocrinol (Lausanne) 2019, 10, 876. [Google Scholar] [CrossRef] [PubMed]
  97. Park, C.H.; Choi, S.H.; Piao, Y.; Kim, S.; Lee, Y.J.; Kim, H.S.; Jeong, S.J.; Rah, J.C.; Seo, J.H.; Lee, J.H.; et al. Glutamate and aspartate impair memory retention and damage hypothalamic neurons in adult mice. Toxicol Lett 2000, 115, 117–125. [Google Scholar] [CrossRef]
  98. Lee, J.; Chung, M.K.; Ro, J.Y. Activation of NMDA receptors leads to phosphorylation of TRPV1 S800 by protein kinase C and A-Kinase anchoring protein 150 in rat trigeminal ganglia. Biochem Biophys Res Commun 2012, 424, 358–363. [Google Scholar] [CrossRef]
  99. Lee, J.; Saloman, J.L.; Weiland, G.; Auh, Q.S.; Chung, M.K.; Ro, J.Y. Functional interactions between NMDA receptors and TRPV1 in trigeminal sensory neurons mediate mechanical hyperalgesia in the rat masseter muscle. Pain 2012, 153, 1514–1524. [Google Scholar] [CrossRef] [PubMed]
  100. Abdollahi, M.; Nikfar, S.; Abdoli, N. Potentiation by nitric oxide synthase inhibitor and calcium channel blocker of aspartame-induced antinociception in the mouse formalin test. Fundam Clin Pharmacol 2001, 15, 117–123. [Google Scholar] [CrossRef] [PubMed]
  101. Collison, K.S.; Makhoul, N.J.; Zaidi, M.Z.; Saleh, S.M.; Andres, B.; Inglis, A.; Al-Rabiah, R.; Al-Mohanna, F.A. Gender dimorphism in aspartame-induced impairment of spatial cognition and insulin sensitivity. PLoS One 2012, 7, e31570. [Google Scholar] [CrossRef]
  102. Errico, F.; Nisticò, R.; Palma, G.; Federici, M.; Affuso, A.; Brilli, E.; Topo, E.; Centonze, D.; Bernardi, G.; Bozzi, Y.; et al. Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Mol Cell Neurosci 2008, 37, 236–246. [Google Scholar] [CrossRef]
  103. Magalhães, P.C.G.; Abadie-Guedes, R.; da Costa Mendonça, M.A.B.; de Souza, A.D.; Guedes, R.C.A. Behavioral and electrophysiological brain effects of aspartame on well-nourished and malnourished rats. Metab Brain Dis 2019, 34, 651–658. [Google Scholar] [CrossRef] [PubMed]
  104. Goerss, A.L.; Wagner, G.C.; Hill, W.L. Acute effects of aspartame on aggression and neurochemistry of rats. Life Sci 2000, 67, 1325–1329. [Google Scholar] [CrossRef]
  105. Lindseth, G.N.; Coolahan, S.E.; Petros, T.V.; Lindseth, P.D. Neurobehavioral effects of aspartame consumption. Res Nurs Health 2014, 37, 185–193. [Google Scholar] [CrossRef]
  106. Affairs, C.o.S. Aspartame. Review of safety issues. Council on Scientific Affairs. JAMA 1985, 254, 400–402. [Google Scholar]
  107. Malkan, S. Aspartame: Decades of Science Point to Serious Health Risks. 2022.
  108. Millstone, E.P.; Dawson, E. EFSA's toxicological assessment of aspartame: was it even-handedly trying to identify possible unreliable positives and unreliable negatives? Arch Public Health 2019, 77, 019–0355. [Google Scholar] [CrossRef]
  109. Lim, U.; Subar, A.F.; Mouw, T.; Hartge, P.; Morton, L.M.; Stolzenberg-Solomon, R.; Campbell, D.; Hollenbeck, A.R.; Schatzkin, A. Consumption of aspartame-containing beverages and incidence of hematopoietic and brain malignancies. Cancer Epidemiol Biomarkers Prev 2006, 15, 1654–1659. [Google Scholar] [CrossRef]
  110. Spiers, P.A.; Sabounjian, L.; Reiner, A.; Myers, D.K.; Wurtman, J.; Schomer, D.L. Aspartame: neuropsychologic and neurophysiologic evaluation of acute and chronic effects. Am J Clin Nutr 1998, 68, 531–537. [Google Scholar] [CrossRef]
  111. Solomi, L.; Rees, G.A.; Redfern, K.M. The acute effects of the non-nutritive sweeteners aspartame and acesulfame-K in UK diet cola on glycaemic response. Int J Food Sci Nutr 2019, 70, 894–900. [Google Scholar] [CrossRef]
  112. Torii, K.; Mimura, T.; Takasaki, Y.; Ichimura, M. Dietary aspartame with protein on plasma and brain amino acids, brain monoamines and behavior in rats. Physiol Behav 1986, 36, 765–771. [Google Scholar] [CrossRef]
  113. Sharma, R.P.; Coulombe, R.A., Jr. Effects of repeated doses of aspartame on serotonin and its metabolite in various regions of the mouse brain. Food Chem Toxicol. 1987, 25, 565–568. [Google Scholar] [CrossRef] [PubMed]
  114. Vences-Mejía, A.; Labra-Ruíz, N.; Hernández-Martínez, N.; Dorado-González, V.; Gómez-Garduño, J.; Pérez-López, I.; Nosti-Palacios, R.; Camacho Carranza, R.; Espinosa-Aguirre, J.J. The effect of aspartame on rat brain xenobiotic-metabolizing enzymes. Hum Exp Toxicol 2006, 25, 453–459. [Google Scholar] [CrossRef] [PubMed]
  115. Abdel Salam, O.M.; Shaffie, N.M.; Sleem, A.A. Hepatoprotective effects of citric acid and aspartame on carbon tetrachloride-induced hepatic damage in rats. EXCLI J 2009, 8, 41–49. [Google Scholar]
  116. Kim, J.Y.; Seo, J.; Cho, K.H. Aspartame-fed zebrafish exhibit acute deaths with swimming defects and saccharin-fed zebrafish have elevation of cholesteryl ester transfer protein activity in hypercholesterolemia. Food Chem Toxicol 2011, 49, 2899–2905. [Google Scholar] [CrossRef] [PubMed]
  117. Choudhary, A.K.; Rathinasamy, S. Effects of aspartame on hsp70, bcl-2 and bax expression in immune organs of Wistar albino rats. J Biomed Res 2016, 30, 427–435. [Google Scholar]
  118. Gul, S.S.; Hamilton, A.R.; Munoz, A.R.; Phupitakphol, T.; Liu, W.; Hyoju, S.K.; Economopoulos, K.P.; Morrison, S.; Hu, D.; Zhang, W.; et al. Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. Appl Physiol Nutr Metab 2017, 42, 77–83. [Google Scholar] [CrossRef]
  119. Helal, E.G.; Abdelaziz, M.A.; Taha, N.M.; El-Gama, M.S. The influence of acesulfame-k and aspartame on some physiological parameters in male albino rats. The Egyptian Journal of Hospital Medicine 2019, 75, 1976–1981. [Google Scholar] [CrossRef]
  120. Nettleton, J.E.; Cho, N.A.; Klancic, T.; Nicolucci, A.C.; Shearer, J.; Borgland, S.L.; Johnston, L.A.; Ramay, H.R.; Noye Tuplin, E.; Chleilat, F.; et al. Maternal low-dose aspartame and stevia consumption with an obesogenic diet alters metabolism, gut microbiota and mesolimbic reward system in rat dams and their offspring. Gut 2020, 69, 1807–1817. [Google Scholar] [CrossRef] [PubMed]
  121. Fareed, S.A.; Mostafa, H.E. Could aspartame exacerbate caffeine effects on renal maturation in rat's offspring? A biochemical and histological study. Birth Defects Res 2021, 113, 90–107. [Google Scholar] [CrossRef] [PubMed]
  122. Bandyopadhyay, A.; Ghoshal, S.; Mukherjee, A. Genotoxicity testing of low-calorie sweeteners: aspartame, acesulfame-K, and saccharin. Drug Chem Toxicol 2008, 31, 447–457. [Google Scholar] [CrossRef]
  123. Fountain, S.B.; Hennes, S.K.; Teyler, T.J. Aspartame exposure and in vitro hippocampal slice excitability and plasticity. Fundam Appl Toxicol 1988, 11, 221–228. [Google Scholar] [CrossRef] [PubMed]
  124. Simintzi, I.; Schulpis, K.H.; Angelogianni, P.; Liapi, C.; Tsakiris, S. The effect of aspartame on acetylcholinesterase activity in hippocampal homogenates of suckling rats. Pharmacol Res 2007, 56, 155–159. [Google Scholar] [CrossRef]
  125. Kashanian, S.; Khodaei, M.M.; Kheirdoosh, F. In vitro DNA binding studies of Aspartame, an artificial sweetener. J Photochem Photobiol B 2013, 120, 104–110. [Google Scholar] [CrossRef]
  126. Çadirci, K.; Tozlu, Ö.Ö.; Türkez, H.; Mardinoğlu, A. The in vitro cytotoxic, genotoxic, and oxidative damage potentials of the oral artificialsweetener aspartame on cultured human blood cells. Turkish J Med Sci 2020, 50, 448–454. [Google Scholar] [CrossRef]
  127. Manion, C.V.; Howard, J.; Ogle, B.; Parkhurst, J.; Edmundson, A. Aspartame effect in sickle cell anemia. Clin Pharmacol Ther 2001, 69, 346–355. [Google Scholar] [CrossRef]
  128. Rios, D.; Ionta, F.Q.; Rebelato, R.; Jordão, M.C.; Wang, L.; Magalhães, A.C.; Honório, H.M. The effect of aspartame and pH changes on the erosive potential of cola drinks in bovine enamel: An in vitro study. J Clin Exp Dent 2018, 10, e933–e937. [Google Scholar] [CrossRef]
  129. Pandurangan, M.; Park, J.; Kim, E. Aspartame downregulates 3T3-L1 differentiation. In Vitro Cell Dev Biol Anim 2014, 50, 851–857. [Google Scholar] [CrossRef]
  130. Sun, D.; Liu, L.; Mao, S.; Zhu, W.; Liu, J. Aspartame supplementation in starter accelerates small intestinal epithelial cell cycle and stimulates secretion of glucagon-like peptide-2 in pre-weaned lambs. J Anim Physiol Anim Nutr (Berl) 2019, 103, 1338–1350. [Google Scholar] [CrossRef] [PubMed]
  131. Chontzopoulou, E.; Papaemmanouil, C.D.; Chatziathanasiadou, M.V.; Kolokouris, D.; Kiriakidi, S.; Konstantinidi, A.; Gerogianni, I.; Tselios, T.; Kostakis, I.K.; Chrysina, E.D.; et al. Molecular investigation of artificial and natural sweeteners as potential anti-inflammatory agents. J Biomol Struct Dyn 2021, 1–13. [Google Scholar] [CrossRef] [PubMed]
Preprints 78674 g001
Figure 1. Main steps related to aspartame discovery, approval, development and use, along with some of the clinical trials, in vivo and in vitro studies evidencing its biological effects (more details in Table A1), and the dynamics of publications describing them.
Figure 1. Main steps related to aspartame discovery, approval, development and use, along with some of the clinical trials, in vivo and in vitro studies evidencing its biological effects (more details in Table A1), and the dynamics of publications describing them.
Preprints 78674 g001
Preprints 78674 g002
Figure 2. Summary of pathways involved in aspartame decomposition, kinetics, metabolism, potential adverse effects at cell level, side effects and relationships with different disorders (abbreviations: PKU – phenylketonuria, NAAT – large neutral aminoacids transporter, BBB – blood-brain barrier, NMDARs – N-methyl-D-aspartate receptors, nNOS – neuronal nitric oxide synthase, NO – nitric oxide, ROS – reactive oxygen species, ACh – acetylcholine, SOD – superoxide dismutase, RBC – red blood cell, IBD – inflammatory bowel diseases, NHL – non-Hodgkin lymphoma, MM – multiple myeloma).
Figure 2. Summary of pathways involved in aspartame decomposition, kinetics, metabolism, potential adverse effects at cell level, side effects and relationships with different disorders (abbreviations: PKU – phenylketonuria, NAAT – large neutral aminoacids transporter, BBB – blood-brain barrier, NMDARs – N-methyl-D-aspartate receptors, nNOS – neuronal nitric oxide synthase, NO – nitric oxide, ROS – reactive oxygen species, ACh – acetylcholine, SOD – superoxide dismutase, RBC – red blood cell, IBD – inflammatory bowel diseases, NHL – non-Hodgkin lymphoma, MM – multiple myeloma).
Preprints 78674 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Role of Ketogenic Diets and Intermittent Fasting in Neurologic Diseases, Cancers and Obesity- A Comprehensive Review of Human Studies

Nikhila Chelikam

et al.

,

2023

D-Amino Acids are Signaling Agents Under Stress, that Broadly Impact Preventive Medicine

Edna Ben Izhak Monselise

,

2019

Chronic Ambient Poisoning

Beth Alderman

,

2022

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated